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Sepsis claims over 215,000 lives in the US annually. Inducible 
glucocorticoids (iGC) is produced during sepsis. However, the precise effects of 
iGC in sepsis remain unclear due to a lack of appropriate animal models. 
Glucocorticoid (GC) insufficiency is associated with a marked increase in 
mortality and occurs in 60% of severe septic patients. Yet the conclusion of GC 
therapy on septic patients is still controversial.  
Scavenger receptor class B type I (SR-BI) in the adrenal mediates the selective 
uptake of cholesteryl ester from lipoproteins for GC synthesis. SR-BI-/- mice 
completely lack iGC during sepsis and are highly susceptible to septic death, 
which presents SR-BI-/- mice as a GC insufficient model. However, SR-BI-/- mice 
display multiple defects contributing to septic death, making it difficult to study 
iGC by using these mice. Therefore, we utilized adrenal-specific SR-BI-/- mice 
(ADR-T SR-BI-/-) generated by adrenal transplantation. As expected, the ADR-T 
SR-BI-/- mice failed to generate iGC under cecal ligation and puncture (CLP)-
induced sepsis and showed a significantly higher mortality than the control mice, 
demonstrating that iGC is essential for preventing septic death. High blood urea 
nitrogen (BUN) was observed in the ADR-T SR-BI-/- mice but not in the control 
mice in CLP, indicating that iGC protects kidney injury in sepsis. Plasma IL-6 was 
remarkably higher in the ADR-T SR-BI-/- mice than the control mice, 
demonstrating an anti-inflammatory effect of iGC in sepsis. The ADR-T SR-BI-/- 
mice also displayed significantly lower phagocytic activity of monocytes and 
neutrophils in the blood and lower activation of T cells in the spleen compared to 
the control mice in CLP, suggesting that iGC is immunomodulatory in sepsis. 
Low-dose GC supplementation significantly improved the survival of SR-BI-/- mice 
in CLP, but did not increase the survival rate of SR-BI+/+ mice in CLP, indicating 
that GC supplementation improves the survival specifically in mice with adrenal 
insufficiency.
ABSTRACT OF DISSERTATION 
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Overall, we revealed that iGC is essential for sepsis survival. iGC prevents 
kidney damage, modulates inflammatory responses and exerts 
immunomodulatory functions in sepsis. GC supplementation specifically 
improves survival of individuals with adrenal insufficiency in sepsis. 
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Chapter 1 Introduction 
1.1 Sepsis 
1.1.1 History of sepsis 
The word “sepsis”, deriving from the Greek word “σήψις”, was first 
introduced by Hippocrates (ca. 460-370 BC) in reference to decomposition or 
putrefaction. Sepsis was described as a form of tissue breakdown; it described 
the processes of putrefaction and decay and was associated with death and 
disease. The concept of sepsis introduced in classical antiquity was used until 
the 19th century. At the beginning of the 19th century, Justus von Liebig 
expanded the theory by claiming that the contact between wounds and oxygen 
was responsible for the development of sepsis. Later, Semmelweis deducted that 
the puerperal fever, a form of sepsis, was caused by “decomposed animal matter 
that entered the blood system” and succeeded in lowering the mortality rate by 
introducing hand washing with a chlorinated lime solution before every 
gynaecological examination. Louis Pasteur (1822-1895) discovered that tiny 
single-cell organisms that we now call bacteria caused putrefaction and correctly 
deducted that these microbes could be causing disease. In 1914, Hugo 
Schottmüller (1867-1936) paved the way for a modern definition of sepsis: 
"Sepsis is present if a focus has developed from which pathogenic bacteria, 
constantly or periodically, invade the blood stream in such a way that this causes 
subjective and objective symptoms." Thus, for the first time, the source of 
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infection as a cause of sepsis came into focus. In pre-antibiotic time, a number of 
patients developed sepsis and the death rate was very high. These patients often 
showed a very low blood pressure, a condition called septic shock. With the 
introduction of antibiotics, the death rate of sepsis was reduced. With 
technological progress, intensive care medicine started to develop, and sepsis 
patients soon became the main patient fraction in intensive care units (ICU). In 
the 1980s, it was discovered that the inflammatory reaction in sepsis patients 
was in the whole body. Hence it became clear that the onset of sepsis did not 
derive from an infectious focus alone, but that the host response against infection 
must in some way play a role. In 1989, Roger C. Bone (1941-1997) established a 
sepsis definition that is still valid today: "Sepsis is defined as an invasion of 
microorganisms and/or their toxins into the bloodstream, along with the 
organism's reaction against this invasion." [1, 2] 
1.1.2 Epidemiology of sepsis 
Contemporarily, despite advances in critical care and anti-microbial 
therapy, sepsis remains a leading cause of death in intensive care units (ICUs).[3] 
Approximately 20-35% of people with severe sepsis and 30-70% of people with 
septic shock die.[4] Sepsis causes millions of deaths globally each year.[5] It is 
estimated that in the United States, sepsis is diagnosed in three per 1,000 people 
each year and leads to 215,000 deaths annually.[6]  According to the data from 
the National Hospital Discharge Survey, the number and rate per 10,000 people 
hospitalized for septicemia or sepsis was more than doubled from 2000 through 
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2008 and 17 % of septicemia or sepsis hospitalizations ended in death, whereas 
only 2 % of other hospitalizations did.[7]  
The incidence of sepsis varies among populations. Males appear to be at 
greater risk of developing sepsis than females.[3, 8] Racial and ethnic origin also 
matters as sepsis appears to be highest among African-American males.[9] 
Elderly people are more susceptible to sepsis. In the United States, patients ≥ 65 
years of age account for nearly 60 percent of all episodes of severe sepsis, and 
this is likely to increase over the next 20 years.[7, 9, 10]  
Sepsis can be triggered by infections in any part of the body, among which 
respiratory infection is the most common cause of sepsis and is associated with 
the highest mortality, followed by abdominal infection and urinary tract 
infection.[11] The contribution of various infectious organisms to the burden of 
sepsis has changed over time.[12, 13] Gram-positive bacteria as a cause of 
sepsis have increased in frequency over time, such that they are now more 
common than gram-negative infection, although the number of cases of gram-
negative sepsis remains substantial.[3, 14, 15] The incidence of fungal sepsis 
has also increased over the past decade, but remains lower than bacterial 
sepsis.[16] Infection of parasites such as falciparum malaria may also cause 
sepsis and requires management in the intensive care unit.[17, 18]  
1.1.3 Definitions for sepsis 
The sepsis syndrome is a continuum of clinical events with increasing 
severity and mortality. In the past, the terms bacteremia, septicemia, sepsis, 
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sepsis syndrome, and septic shock were used interchangeably, which lead to an 
imprecise understanding of sepsis. In 1991, the American College of Chest 
Physicians (ACCP) and Society of Critical Care Medicine (SCCM) published 
consensus definitions for sepsis.[19] These definitions were reconsidered in 2001 
during an International Sepsis Definitions Conference and again in 2012.[12, 20] 
Table 1.1 shows the current definitions for sepsis. 
The sepsis consensus definitions recognize a series of progressive stages 
in sepsis, including the systemic inflammatory syndrome (SIRS), sepsis, severe 
sepsis and septic shock. SIRS is a reference for a range of clinical symptoms 
that result from a systemic activation of the innate responses, regardless of the 
cause. Thus SIRS may also arise from non-infectious insults. Sepsis is defined 
as the SIRS resulting from infection. Uncomplicated sepsis, such as that caused 
by flu or urinary infection, is common and may not need hospital treatment. 
Severe sepsis arises when sepsis occurs in combination with multiple organ 
dysfunction syndrome (MODS). Because of problems with their vital organs, 
people with severe sepsis are more likely to die (mortality ≈30%) than those with 
uncomplicated sepsis. Septic shock occurs when sepsis is complicated by shock. 
Patients with septic shock are very ill and need rapid emergency admission to 
the hospital intensive care unit (ICU). Despite active treatment in the ICU, the 
death rate of septic shock patients is around 50 %.  
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Table 1.1 Clinical definitions for sepsis.  
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1.1.4 Sepsis pathophysiology 
Sepsis begins as the inflammatory response to an infection. The 
inflammatory response to an infection is initiated by the recognition of the 
microorganisms and the activation of the innate immune system. Activation of the 
innate immune system involves the production of oxygen radicals, the release of 
cytokines and inflammatory mediators and the activation of complement system. 
Meanwhile, coagulation is activated due to endothelial injuries and is enhanced 
by pro-inflammatory cytokines. In a typical inflammatory response, the oxygen 
radicals, cytokines and activated complement are generated to defense and kill 
invasive pathogens, which can be controlled by the host. However, when the 
host is unable to successfully constrain an infection, a complex dysregulation of 
inflammation arise and sepsis occurs. The factors underlie a typical inflammatory 
response all contribute to the pathophysiology of sepsis (Figure 1.1).  
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Figure 1.1 Pathogenic networks during sepsis.  
LPS and other microbial products simultaneously activate the production of cytokine and 
inflammatory mediators, the complement system and the coagulation cascade that 
contributes to the pathophysiology of sepsis and septic shock. Reduced vascular 
stability and microvascular occlusion leads to coagulation, fever, vasodilatation, and 
capillary leakage, provoking hypoperfusion and inadequate oxygenation and thus organ 
failure.[21] 
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1.1.4.1 Initiation of the inflammatory response to an infection 
The inflammatory response to an invading pathogen is initiated by the 
recognition of the microorganisms and the activation of the innate immune 
system. After entering tissues, many pathogens are recognized, ingested, and 
killed by phagocytes. Two main types of phagocytes are mononuclear 
phagocytes, or macrophages, which reside in the tissues and the neutrophils. In 
most cases, the tissue macrophages are the first cells to encounter most 
pathogens, and are soon reinforced by the recruitment of large numbers of 
neutrophils to the site of infection. Macrophages and neutrophils recognize 
pathogens by means of cell surface receptors, such as the macrophage 
mannose receptor and scavenger receptor. In addition, the repeating patterns of 
molecular structures on the surface of microorganisms, or called pathogen 
associated molecular patterns (PAMPs), can be recognized by specific pathogen 
recognition receptors (PRRs). Typical PAMPs include lipopolysaccharides (LPS) 
from gram-negative bacteria, lipoteichoic acid (LTA) and peptidoglycan from 
gram-positive bacteria as well as CpG DNA (bacterial DNA rich in cytosine-
phosphate diesterguanosine), bacterial flagellins and double-stranded RNAs (ds 
RNA) from viruses. Correspondingly, these PAMPs are recognized by three 
families of PRRs: toll-like receptors (TLRs), intracellular nucleotide-binding 
oligomerisation domain (NOD) proteins and peptidoglycan recognition 
proteins.[22, 23] These PRRs distinguish different types of pathogens and signal 
to direct appropriate immune responses to the pathogens.  
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In many cases, binding of a pathogen to the cell-surface receptors in 
phagocytes leads to phagocytosis, in which the pathogens are killed in acidified 
phagosomes or killed in phagolysosomes formed by the fusion of phagosomes 
and lysosomes. Macrophages and neutrophils also produce a variety of toxic 
products to help kill the engulfed microorganism. These involve the anti-microbial 
peptides such as defensins and cationic proteins, nitric oxide (NO), and reactive 
oxygen species(ROS) including superoxide anion (O2-), hydrogen peroxide 
(H2O2), and hydroxyl radicals(·HO). In sepsis, however, these is a massive 
production, which leads to the systemic damage of vascular endothelium.[24, 25]  
1.1.4.2 Production of cytokines, chemokines and other chemical mediators 
Another important effect of the interaction between pathogen and tissue 
macrophages is the activation of macrophages to release cytokines, chemokines 
and other chemical mediators that attract neutrophils and plasma proteins to the 
infection site. The binding of a microbial molecule to its specific TLR or NOD 
results in the signal transmission that leads to the activation of nuclear 
transcription factor NF-κB, which drives the transcription of a large range of 
important pro-inflammatory cytokine and chemokine genes.[26-29] Pro- 
inflammatory cytokines (i.e. tumor necrosis factor α [TNF-α], interleukin 1 [IL-1], 
IL-6, IL-12 and high-mobility group box protein 1 [HMGB1]), chemokines (e.g. 
monocyte chemotactic protein-1 [MCP-1] and IL-8) as well as lipid mediators (e.g. 
platelet-activating factor [PAF], prostaglandins [PGs] and leukotrienes) are 
released. This secretion of inflammatory cytokines provokes an activation of 
surrounding innate immune cells and later activation of adaptive immune cells. 
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Chemokines mainly function as chemoattractants for leucocytes, recruiting 
monocytes, neutrophils, and other effector cells from the blood to the sites of 
infection in order to enhance the defense against the pathogens. In favorable 
situation, the infection-induced immune response is tightly controlled by different 
mechanisms that are triggered by PRRs themselves to control the process, 
including the inhibition of the TLR-related intracellular signaling, production of 
soluble receptors and antagonists that neutralize extracellular pro-inflammatory 
cytokine and production of anti-inflammatory cytokines (e.g. IL-10).[30, 31] 
However, in sepsis, this inflammatory response is dysregulated and 
overwhelming levels of pro-inflammatory cytokines are produced, which 
contributes to the endothelial damage and promotes coagulation in sepsis.[32, 33] 
In particular, the systemic release of TNF-α causes vasodilation, which leads to a 
drop in blood pressure and increased vascular permeability.[34]  
Another activated enzyme of major importance is inducible nitric oxide 
synthease (iNOS), which is induced by NF-κB. Sepsis is accompanied by the 
production of excess NO.[35, 36] Excess NO in sepsis provokes a systemic 
vasodilation, which contributes to septic shock and can also induce hepatocyte 
damage, increase gut epithelial permeability [37], impair neutrophil migration to 
infection site [38-40], and exert cytotoxic effects through the formation of ONOO-, 
resulting in damage to DNA, membrane phospholipids and mitochondria.[41] 
1.1.4.3 Activation of the complement system 
Microorganisms and endotoxins also turn on the humoral innate immune 
responses. The complement system can be activated by the binding of 
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complement component C1q to an antibody complexed with antigen, by the 
direct binding of C1q to the pathogen surface, or by the binding of C1q to the C-
reactive protein bound to the pathogen. Activation of the complement system 
initiates a series of cleavage reactions that culminates in the formation of C3 
convertase, which cleaves complement component C3 into C3b and C3a. C3b 
can mediate the opsonization of pathogens that facilitates phagocytosis. In 
addition, binding of C3b to C3 convertase further forms a C5 convertase which 
cleaves C5 to C5a and C5b. C3a and C5a are peptide mediators of inflammation. 
They are potent leukocyte chemoattractants and can also induce degranulation 
of basophilic granulocytes and mast cells, and thereby lead to a release of 
histamine, serotonin, and leukotriene B4 (LTB4). These molecules further 
increase vasodilatation. Sepsis is accompanied by the excess production of C5a 
and C3a. A high level of plasma C5a in septic patients correlates with poor 
outcome.[42]  
1.1.4.4 Activation of the coagulation cascade 
The activation of coagulation at the site of infection is important to block 
small blood vessels and therefore to prevent further spreading of pathogens by 
the formation of fibrin. However, in sepsis, coagulation is increased and the 
mechanisms that favor fibrinolysis (fibrin breakdown by plasmin) are reduced. 
The endothelial injury at the site of infection, microbial components as well as the 
pro-inflammatory cytokines initiate and promote coagulation pathways leading to 
the increased expression of tissue factor (TF) on polymorphonuclear leukocytes 
(PMNs)  and endothelial cells. Exposure of the coagulation system to TF 
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activates a series of proteolytic cascades, which result in the conversion of 
prothrombin to thrombin. Thrombin in turn catalyzes the conversion of fibrinogen 
to fibrin. Meanwhile, there is an increase in plasminogen activator inhibitor-1 
(PAI-1) that inhibits fibrinolysis by preventing transformation of plasminogen into 
active plasmin. The net result is enhanced production and reduced removal of 
fibrin. This disorder of coagulation leads to the deposition of fibrin clots in small 
blood vessels and inadequate tissue perfusion.[21]  
1.1.4.5 Adaptive immunity in sepsis 
Adaptive immunity can be activated when the infection is not constrained 
in the local site. Unlike innate immunity which plays a major role in the earliest 
phases of the infection, adaptive immunity needs several days for clonal 
expansion and differentiation of naive lymphocytes into effector T cells and 
antibody-secreting B cells that, in most cases, effectively target the pathogen for 
elimination. In the adaptive immunity, the antigen presenting cells (APCs), 
including dendritic cells, B cells and macrophages, present peptide fragments of 
phagocyted micro-organisms to CD4+ T cells by their major histocompatibility 
complex II (MHCII) and initiate the antigen specific immune response. CD4+ T 
cells then clonally expand with the actions of IL-2 induced by the activation of T 
cell receptor (TCR)-associated CD3 complex and the actions of co-stimulatory 
molecules induced on the APCs during their interaction with microorganisms. 
CD4+ T cells then differentiate to effector cells, which can migrate to the site of 
infection and further differentiate into a variety of T helper cell subsets, including 
Th1, Th2 and Th17 cells.  
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Adaptive immune cells classically are considered as bystanders in the 
inflammatory responses in sepsis; however, recent studies have shown that both 
T cells and B cells play a protective role in sepsis. Hotchkiss, et al. have 
demonstrated that Rag1−/− mice that lack mature T and B lymphocytes have 
increased mortality after bacterial sepsis.[43, 44] Although a later study by 
Bosmann M et al. showed no difference in the survival rate between Rag1-/- mice 
and wild type mice in cecal ligation and puncture (CLP)-induced sepsis[45], 
Kelly-Scumpia, K.M. et al. recently have demonstrated a protective role of IFN-I-
activated B cells in sepsis by enhancing early innate immune response.[46] In 
addition, Inoue, M et al. have demonstrated that T cells can interact with 
macrophages in the spleen and down-regulate TNF-mediated inflammation in 
LPS-induced endotoxemia.[47]  
1.1.5 Multiple organ damage in sepsis 
In sepsis, organ damage is frequently observed in vital organs such as the 
kidneys, liver, heart, and lungs that are quickly compromised by the failure of 
blood perfusion. Multiple organ failure contributes to an increased mortality in 
septic patients.[3] The pathogenesis of organ damage, however, is incompletely 
understood. Tissue hypoperfusion and hypoxia are important reasons for the 
organ damage. The mechanisms may involve the decreased microperfusion 
secondary to thrombi formation, reduced red blood cell deformability, blood 
maldistribution, and tissue edema caused by increased capillary permeability. In 
addition, NO-induced impairment in mitochondrial respiration impacts the 
utilization of available oxygen by the cells.[48] Infiltration of neutrophils and 
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lymphocytes can also damage tissue directly by releasing lysosomal enzymes 
and superoxide-derived free radicals.[49]  
1.1.6 Immunosuppression in sepsis and “compensatory anti-inflammatory 
response syndrome” 
Traditionally, an exacerbated production of pro-inflammatory mediators as 
illustrated by the so-called “cytokine storm” was considered to be the cause of 
sepsis.[50] However, recent studies have shown that anti-inflammatory 
responses occur early and simultaneously in sepsis as well.[51] Therefore, the 
host immune response to sepsis is currently considered to be characterized by 
two established hemodynamic phases that may overlap. The initial phase, or the 
hyper-dynamic phase, is defined as a massive production of pro-inflammatory 
cytokines, chemokines and reactive oxygen species by macrophages and 
neutrophils that affects vascular permeability (leading to hypotension) and 
cardiac function and induces metabolic changes culminating in tissue necrosis as 
well as organ failure. The second phase, or the hypo-dynamic phase, is an anti-
inflammatory process involving altered monocyte antigen presentation, 
decreased lymphocyte proliferation and responsiveness and promoted 
lymphocyte apoptosis and anergy.[52, 53] The latter state, also known as 
immunosuppression or immune depression, sharply increases the risk of 
nosocomial infections and ultimately, death.[54] Figure 1.2 shows a simplified 
paradigm of the host response to sepsis.  
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Figure 1.2 Simplified paradigm of the host response to sepsis.   
Progression of sepsis is complex, nonlinear, and varies from individual patient to another. 
(A) The initial response in previously healthy patients with severe sepsis is typified by an 
overwhelming hyper-inflammatory phase. The hyper-inflammation contributes to early 
deaths in sepsis. (B) Patients who survived the first hyper-inflammatory phase may 
develop immunosuppression due to the alterations in immunity during sepsis. This 
immunosuppressive status makes them susceptible to nosocomial infection, which also 
causes death. [55] 
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In clinic, the release of anti-inflammatory mediators appears to be 
exacerbated in septic patients, which can be illustrated by the strong relationship 
between high levels of plasma anti-inflammatory mediators and poor 
outcome.[56] In addition, the plasma of sepsis patients has the capacity to inhibit 
leukocyte functions and is considered an immunosuppressive milieu.[57] 
Furthermore, the fact that intensive care patients are highly susceptible to 
nosocomial infection indicates an alteration of their immune status. Thus, words 
such as anergy [58], immunodepression [59] and immunoparalysis [60] have 
been employed to define such immune status. In 1997, Roger Bone coined a 
new acronym CARS for “compensatory anti-inflammatory response syndrome” to 
describe the properties of immune status in patients with sepsis.[61, 62] 
The immunosuppression in sepsis involves the alterations in both innate 
immunity and adaptive immunity. In innate immunity, sepsis can reduce the 
phagocytic activity of neutrophils. Phagocytosis by neutrophils of septic patients 
was reported to be lower than that of neutrophils from control patients, probably 
due to the immaturity of neutrophils in septic patients.[63] The impaired 
phagocytic activity of neutrophils in septic patients is associated with a high 
mortality sepsis.[64] However, no difference has been observed in the phagocytic 
activity of monocytes in the septic patients.[64] In adaptive immunity, sepsis-
induced lymphocyte apoptosis may play an important role in inducing 
immunosuppression. Prevention of lymphocyte cell death in experimental sepsis 
can improve the survival of mice.[65] Profound progressive loss of B and CD4 T 
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helper cells was observed in septic patients, which is likely mediated by both 
death receptor and mitochondrial-mediated apoptotic pathway.[66, 67]  
A major consequence of CARS is the increased susceptibility to 
nosocomial infections. It has been indicated that the severity of the 
immunosuppression is associated with an increased probability of developing 
severe sepsis.[68] In line, “two hit” animal models have suggested that an 
enhanced susceptibility to a sublethal infection occurs following a first septic 
insult.[69-71] A first insult, usually a peritonitis which is experimentally induced by 
CLP, renders the animal more susceptible to a secondary bacterial or viral lung 
infection.[69-71] In fact, most of the patients with sepsis or septic shock 
undergoing an immunosuppression do not die from the initial systemic infection, 
but from a second or third hit, that they acquire in hospital. [54, 72] 
Thus, a model of immune disorders in sepsis is proposed. In the beginning 
of sepsis, the pro-inflammatory mediators (referred to as the SIRS) and the anti-
inflammatory mediators (referred to as the CARS) are balanced. Inflammation 
activates the SIRS mediators, which activates the host immune-inflammatory 
system and can be de-activated through the expression of CARS mediators; or 
once CARS mediators are more abundant. As sepsis develops, the expression of 
SIRS and CARS is out of control, resulting in an exaggerated and dysfunctional 
inflammatory response.[73] The dysregulation of inflammatory and immune 
responses may be different from individual to individual. This heterogeneity of 
septic patients makes it difficult to treat sepsis clinically.[74] (Figure 1.3) 
18 
 
 
Figure 1.3 Sepsis and CARS  
The host inflammatory response during inflammation can be viewed as a balanced 
response between pro-inflammatory mediators (referred to as the SIRS) and anti-
inflammatory mediators (referred to as the CARS). Inflammation activates the SIRS 
mediators such as TNF-α, IL-1, IL-6 and IL-12, which activate the host immune-
inflammatory system and can be de-activated through the expression of CARS 
mediators, including TGF-β, IL-4, IL-10 and IL-13; or once CARS mediators are more 
abundant. During the development of sepsis, the expression of SIRS and CARS is out of 
control, resulting in an exaggerated and dysfunctional inflammatory response.[73]
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1.2 Glucocorticoids (GC) 
1.2.1 Synthesis of GC 
Glucocorticoids (GC) is a class of steroid hormones. The name 
glucocorticoid derives from its role in the regulation of the metabolism of glucose, 
its synthesis in adrenal cortex and its steroidal structure. Adrenal glands are the 
main source of GC in circulation. Each gland is made of two parts: the medulla 
and the cortex. The medulla belongs to the sympathetic system and produces 
catecholamine (epinephrine, norepinephrine and dopamine). The cortex has 
three zonas. From the outerior to the interior is the zona glomerulosa which 
secretes mineralocorticoids (aldosterone and desoxycorticosterone); the zona 
fasciculata which produces GC (mainly cortisol in human and corticosterone in 
rodents); and the zona reticularis which produces androstenedione, a metabolic 
intermediate in the biosynthesis of the androgen and estrogen sex steroids. The 
hormones secreted from adrenal cortex all derive from cholesterol following a 
cascade of enzymatic reactions, as shown in Figure 1.4.  
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Figure 1.4 Synthesis of GC in adrenal glands.  
Steroid hormones are synthesized in the cortex of adrenal glands which contain zona 
glomerulosa, zona fasciculata and zona reticularis. Each zona is distinguished for the 
synthesis of different kinds of steroid hormones through specific enzymes. Cholesterol is 
the common substrate for steroid hormones. GC, mainly cortisol in human and 
corticosterone in rodents, are synthesized in zona fasciculata. Mineralocorticoids, mainly 
aldosterone, are synthesized from zona glomerulosa. Androstenedione, a common 
precursor for sex hormone, is produced from zona reticularis.  
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Free cholesterol is the substrate for the glucocorticoid synthesis. In 
steroidogenic cells, about 80% cholesterol required for steroidogenesis comes 
from exogenous sources, namely circulating lipoproteins, and about 20% of the 
cholesterol comes from local de novo synthesis from acetate (acetyl CoA).[75] 
Exogenous cholesterol esters from lipoproteins can be delivered by either 
receptor-mediated endocytic uptake or “selective” cellular uptake. Low-density 
lipoprotein (LDL) receptor mediates the endocytic uptake of LDL, or other 
apolipoprotein B-or apolipoprotein E-containing lipoproteins, where the intact 
lipoprotein is internalized and degraded in lysosomes.[76] The cholesterol esters 
delivered via this pathway are hydrolyzed to free cholesterol in lysosomes. 
Scavenger receptor B1 (SR-BI) mediates the “selective” uptake of lipoprotein 
cholesterol esters in which SR-BI selectively delivers the cholesteryl esters into 
cells without internalizing the lipoprotein particle itself. Selectively-delivered 
cholesteryl esters are hydrolyzed by neutral cholesteryl ester hydrolase 
(hormone-sensitive lipase, HSL).[77] Unesterified cholesterol is also derived from 
the hydrolysis of cholesteryl esters (CE) stored in lipid droplets through the 
actions of HSL or via endogenous synthesis from acetyl CoA via the rate limiting 
enzyme hydroxymethylglutaryl coenzyme A reductase (HMG-CoA reductase). 
Unesterified cholesterol can be esterified for storage in lipid droplets by acyl-
coenzyme A:cholesterol acyltransferase (ACAT) or can be transported into 
mitochondria via steroidogenic acute regulatory protein (StAR) for metabolism by 
cholesterol side chain cleavage enzyme (CYP11A1). (Figure 1.5)  
22 
 
 
Figure 1.5 Sources of cholesterol for the synthesis of GC in adrenal steroidogenic 
cells.  
Cholesterol is the substrate for the synthesis of GC. Uptake of cholesterol from 
lipoproteins involves selective uptake of high-density lipoprotein (HDL) cholesteryl esters 
via SR-BI and the endocytic uptake of low-density lipoprotein (LDL) cholesteryl esters 
via LDL receptor. Selectively delivered cholesteryl esters are hydrolyzed by hormone-
sensitive lipase (HSL), whereas cholesteryl esters delivered by receptor-mediated 
endocytosis are hydrolyzed to free cholesterol in lysosomes. Free cholesterol is also 
derived from the hydrolysis of cholesteryl esters (CE) stored in lipid droplets through the 
actions of HSL or via endogenous synthesis from acetyl CoA via the rate limiting enzyme 
hydroxymethylglutaryl coenzyme A reductase (HMG CoA Red). For steroidogenesis, 
free cholesterol is transported into mitochondria via steroidogenic acute regulatory 
protein (StAR) for metabolism by cholesterol side chain cleavage enzyme (CYP11A1). 
[78] 
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1.2.2 Metabolism of GC 
The major site of GC metabolism is the liver, where GC is reduced, 
oxidized, or hydroxylated. The products of these modifications are made water 
soluble by conjugation with sulfate or glucuronic acid to facilitate their excretion in 
urine. Many enzymes are involved in these processes of GC metabolism, such 
as 5α-reductases, 5β-reductases, and 3α-hydroxysteroid dehydrogenases in the 
reduction, the CYP3A4 enzyme in the hydroxylation, uridine 
diphosphoglucouronosyl transferases [79] and sulfotransferases [80] in the 
conjugation. 11β-hydroxysteroid dehydrogenase (11-β-HSD1) is also a key 
enzyme in glucocorticoid metabolism, with both dehydrogenase and reductase 
activities.[81]  
1.2.3 Basal GC and inducible GC (iGC)  
Under normal conditions, the synthesis and release of GC is regulated by 
the hypothalamic-pituitary-adrenal (HPA) axis in a feedback manner. The 
paraventricular hypothalamus secretes corticotropin releasing hormone (CRH) 
into the hypothalamic-pituitary venous system and enhances the pituitary 
production of adrenocorticotrophic hormone (ACTH) yielded from 
proopiomelanocortin (POMC). ACTH in circulation applies a trophic action on the 
adrenal glands, increasing the production and releasing of GC. GC feeds back 
on the HPA axis negatively, reducing the production of CRH and ACTH. Basal 
plasma GC concentrations display a circadian rhythm reaching the zenith 
between 6-8 am and nadir at midnight.[82] Circulating basal GC is important for 
maintaining organismal homeostasis and is thought to have permissive effects: at 
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basal levels, glucocorticoids help the organism prepare for subsequent energetic 
challenges and potentially enhance the initial response to future stressors.[83]  
Under stressed conditions such as sepsis, the rhythm and feedback of 
basal GC are lost. Circulating and locally expressed pro-inflammatory mediators, 
especially cytokine TNF-α, IL-1β and IL-6 activate the HPA axis independently 
and synergistically. Afferent vagal fibbers at local tissue also stimulate the HPA 
axis after sensing the inflammatory threat.[84] In addition, the production of 
cortisol binding globulin (CBG) decreases at the same time, which further 
increases the plasma concentration of free GC. Consequently, the level of 
circulating GC goes up. Our study has been focused on the GC produced upon 
sepsis, which I call inducible GC (iGC). (Figure 1.6) 
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Figure 1.6 Regulation of GC under basal conditions and in sepsis.  
Under basal conditions, the production of GC is tightly regulated by the hypothalamic-
pituitary-adrenal (HPA) axis in a feedback pattern. In sepsis, the immune and 
inflammatory reaction produces local and systemic inflammatory cytokines and 
mediators, which activate the HPA axis directly and indirectly through the activation of 
stress system. In this case, the feedback is lost and the inducible GC (iGC) is produced. 
CRH, corticotropin releasing hormone; ACTH, adrenocorticotrophic hormone 
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1.2.4 Synthetic GC 
Most of research on the function of GC is conducted using synthetic GC. 
In humans, these include prednisolone and methylprednisolone; in animal 
models and in vitro, dexamethasone is most commonly used. However, because 
synthetic GC has different properties from endogenous GC, studies of synthetic 
GC may have provided an over-simplified view of the actions of GC. 
 Modification of the natural GC yields synthetic GC that may have more 
potent glucocorticoid activity as well as an increase in mineral corticoid potency. 
In contrast to natural GC with high affinity for CBG, synthetic steroids other than 
prednisolone either bind weakly to albumin (two-thirds) or circulate as free steroid 
(one-third). Exogenous GC is subject to the same reduction, oxidation, 
hydroxylation, and conjugation reactions as endogenous steroids. However, the 
plasma half-lives of synthetic GC are generally longer than those of endogenous 
GC.[85-87] GC that are fluorinated at the 6-alpha or 9-alpha position 
(dexamethasone, fludrocortisone, betamethasone) or methylated at the 6-alpha 
position (methylprednisolone), or methyloxazoline at position 16,17 (deflazacort), 
are protected from oxidation inactivation by the type 2 11-β-hydroxysteroid 
dehydrogenase (11β-HSD2) [88], which may explain their longer activity than 
cortisol. Overall, the variation in the susceptibility to metabolism by 11-β-
hydroxysteroid dehydrogenase and in the binding affinities for GR and MR leads 
to the diversity of synthetic GC in ant-inflammatory or mineralocorticoid potency 
and duration of action.[89] (Table 1.2)  
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Table 1.2 GC in clinic. 
 
Modification of the natural GC yields synthetic GC that may have more potent 
glucocorticoid activity as well as an increase in mineral corticoid potency. The resistance 
to the oxidation inactivation by the 11β-HSD2 contributes to a longer half-life of synthetic 
GC than that of endogenous GC.  
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1.2.5 Molecular mechanisms of GC action 
Free GC is the biologically active form of GC. However, under normal 
conditions, 90-95 % of plasma cortisol, the main GC in human, is bound to 
albumin and cortisol binding globulin (CBG). The CBG-bound cortisol has 
restricted access to target cells.[90, 91] At inflammatory sites, CBG acts as a 
substrate for elastase produced by neutrophils, allowing localized delivery of 
cortisol.[91] Cortisol then can freely cross the cell’s membrane, or it may interact 
with specific membrane binding sites. Alternatively, cortisol is inactivated by the 
action of type 2 11-β-hydroxysteroid dehydrogenase (11-β HSD2), which 
converts cortisol to cortisone, the inactivate form. The 11-β HSD2 is found mainly 
in mineralocorticoid target tissues (kidney, colon, salivary glands) and in the 
placenta. Conversely, cortisone can be converted into cortisol by type 1 11β-
hydroxysteroid dehydrogenase (11-β-HSD1) converts cortisone into cortisol, 
which is expressed in many glucocorticoid target tissues.[92, 93]  
GC exerts their effects mainly by binding to corticosteroid receptors. There 
are two types of corticosteroid receptors: the type I receptor, which is also 
referred to as the mineralocorticoid receptor (MR) and the type II receptor, which 
is commonly known as the glucocorticoid receptor (GR). In classical 
mineralocorticoid target tissues involved in electrolyte and volume regulation, the 
MR is co-localized with 11-β-HSD2 and thus inactivates GC. (Figure 1.7) 
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Figure 1.7 11β-Hydroxysteroid dehydrogenases modulate GC action. 
11β-Hydroxysteroid dehydrogenases (11β-HSDs) modulate the activation and 
inactivation of GC. 11-β HSD2 inactivates GC and 11-β-HSD1, conversely converts the 
inactive form into cortisol. In mineralcorticoid target tissues, the mineralcorticoid receptor 
co-localizes with 11-β HSD2 and inactivates GC. In contrast, glucocorticoid target 
tissues express 11-β-HSD1, which allows GC to exert its functions. CNS, central 
nervous system 
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Glucocorticoid receptor (GR) is a 94 kDa heterodimeric protein, which 
belongs to the nuclear receptor family. The human glucocorticoid receptor gene 
(GR) is located on chromosome 5 and is responsible for the expression of α and 
β subunits. Like the other steroid receptors[94], GR has three major distinct 
functional domains- the N-terminal or immunogenic domain, the DNA binding 
domain (DBD), and the ligand-binding domain (LBD).[95] GRα in unbound state 
is located primarily in the cytoplasm as part of a hetero-oligomeric complex that 
contains heat shock proteins (HSPs) 90, 70, 50 and 20 and, possibly other 
proteins as well.[96] The free cortisol can enter into the cell and bind to the 
intracellular glucocorticoid receptor type α (GRα). The GR isoform β (GRβ) does 
not itself bind corticosteroids and resides constitutively in the nucleus of cells.[96-
100]. 
Most of the actions of GC are attributable to the transcriptional effects of 
GR.[101] After binding to an agonist ligand, GR undergoes conformational 
changes, dissociats from the HSPs and other chaperone proteins, and 
translocates into the nucleus as a monomer or dimer by means of an active ATP-
dependent process mediated by its nuclear localization signals. Once in the 
nucleus, ligand-activated GR dimers interact directly with glucocorticoid-
responsive elements (GREs) in the promoter regions of target genes. Ligand-
activated GR monomers also interact with other transcription factors at the 
cytoplasmic level and thus indirectly regulate the activity of the latter on their own 
target genes [96]. The ability of GR to inhibit the activity of crucial transcriptional 
regulator of pro-inflammatory genes including NF-κB and activating protein-1 
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(AP-1) is believed as an important mechanism for the anti-inflammatory action of 
GC. In addition, GC can also signal through membrane-associated receptors 
(non-genomic pathways) through a GR-dependent or independent manner, 
which contributes to the quick actions of GC.[102, 103]  
GC has been considered as an anti-inflammatory and immunosuppressive 
agent [101] due to its inhibitory effects on the pro-inflammatory cytokines and 
suppressive actions on immune cells, such as inducing the apoptosis of 
lymphocytes [104] and inhibiting the function of T lymphocytes [105]. However, 
some recent studies challenged this conventional concept. In vitro culture of 
macrophages with the treatment of corticosterone showed that corticosterone 
exerts opposing effects on macrophage functions in a concentration-dependent 
manner. Low-corticosterone treatment can enhance the macrophage production 
of NO, chemotaxis of macrophages and the phagocytosis of E. coli by 
macrophages, whereas high-corticosterone treatment represses these 
macrophages functions.[106, 107] In addition, it has been demonstrated that GC 
can regulate genes involved in the phagocytosis of monocytes and leads to a 
significant increase in the phagocytosis of latex beads and live parasites by the 
cultured human monocytes.[108] These findings led us to ask the question that 
whether or not iGC has actions to promote immunity in sepsis.  
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1.3 SR-BI  
1.3.1 Basics of SR-BI 
Scavenger receptor class B, type I (SR-BI, gene name SCARB1) is a 
75kDa cell surface glycoprotein that belongs to the CD36 superfamily and has 
the common structural features of this family, including membrane-associated 
hydrophobic regions near the N- and C-termini, a large extracellular loop that 
comprises the portion of the peptide sequence between the two membrane-
bound end regions, and several sites of N-linked glycosylation.[109-111] 
Although SR-BI is expressed in many mammalian tissues and cell types, it is 
most highly expressed in tissues that are dependent on HDL cholesterol for bile 
acid or hormone synthesis, including liver, ovary, testes and adrenal glands.[112, 
113]  
SR-BI binds to a variety of ligands including native and modified 
lipoproteins, modified serum proteins such as maleylated serum albumin, lipid 
vesicles containing anionic phospholipids, apoptotic cells and bacterial cell 
surface components such as LPS.[114, 115] Correspondingly, SR-BI has 
multiple functions.  
1.3.2 SR-BI as a multi-functional protein 
The best-known function of SR-BI is to serve as the HDL receptor.[116] 
Studies of knockout and transgenic mice have revealed that SR-BI plays a critical 
role in HDL metabolism, being a very efficient receptor for cholesterol and 
cholesteryl ester transport between cells and HDL.[116-119] Deficiency of SR-BI 
33 
 
leads to a disruption of cholesterol metabolism that is characterized by abnormal 
HDLs which are larger in size and enriched with free cholesterol. Thus, SR-BI-
deficient mice develop hypercholesterolemia with a remarkable increase in 
plasma free cholesterol and a high ratio of plasma unesterified cholesterol (UC)-
to-total cholesterol (TC, unesterified plus esterified cholesterol). The increase in 
plasma UC-to-TC ratio in SR-BI-deficient mice leads to the increase of free 
cholesterol in red blood cells [120] and platelets in circulation [121]. Deposition of 
free cholesterol in red blood cells in SR-BI-deficient mice contributes to their 
phenotypes of reticulocytosis (an increase in reticulocytes in blood) and impairs 
the development of erythrocytes.[120, 122] The high unesterified cholesterol in 
platelets in SR-BI-deficient mice also contributes to their abnormal morphologies, 
elevated rates of clearance of platelets from circulation and defects in ADP-
induced aggregation.[123-125] These abnormalities in platelets in mice are 
associated with an increased susceptibility to thrombosis [126]. In addition, as 
the HDL receptor, SR-BI mediates the activation of endothelial nitric oxide 
synthase (eNOS) by HDL, which leads to increased production of NO [127-130] 
and can induce a ligand-independent apoptotic pathway that is regulated by 
eNOS and HDL [131].  
SR-BI is also important in immunity. In innate immunity, SR-BI mediates 
the uptake of gram-negative bacteria, gram-positive bacteria, LPS and LTA in 
macrophages, thus it facilitates the clearance of bacteria and the alleviation of 
inflammation.[132, 133] Recently, studies have revealed that SR-BI also 
mediates HCV entry [134-136], which is very likely attributed to the lipid transfer 
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function of SR-BI. [137] Paradoxically, SR-BI may also be important in initiating 
the host defense against HCV, as dendritic cells depend on SR-BI to uptake 
HCV.[138] In adaptive immunity, SR-BI is critical in maintaining lymphocyte 
homeostasis, as indicated by an imbalanced lymphocyte expansion in the spleen 
and the development of autoimmune disorders in SR-BI-deficient mice.[139] The 
adaptive immune defects in SR-BI-deficient mice are at least partly attributed to 
their abnormal HDL particles which are dysfunctional in inhibiting anti-CD3-
stimulated T cell proliferation and LPS-induced B cell proliferation.[139]  
1.3.3 SR-BI and GC synthesis 
While both SR-BI and LDL receptor participate in the uptake of cholesterol 
from circulating lipoproteins, human studies support that the SR-BI-mediated 
pathway, rather than the other is more important for the steroidogenic function of 
adrenal glands. In homozygous familial hypercholesterolemia patients who have 
complete LDL-receptor deficiency, the adrenal cortex can respond to a single 
injection of ACTH with a normal increase in corticosteroid production [140] and 
only present a mildly reduced function upon a prolonged stimulation (24 to 36 h) 
with ACTH [141]. Additionally, a 50 % reduction in the number of high affinity LDL 
receptors in heterozygous familial hypercholesterolemia patients does not result 
in any impairment in the delivery of cholesterol to the adrenal cortex even during 
conditions of maximal corticosteroid production (36 h i.v. infusion of ACTH).[119] 
In contrast, carriers of the P297S mutation, a functional mutation of SR-BI, have 
attenuated adrenal steroidogenesis, as evidenced by decreased urinary 
excretion of sterol metabolites, a higher level of cortisol-binding globulin in the 
35 
 
plasma, a decreased response to corticotropin stimulation, and symptoms of 
diminished adrenal function such as fatigue and dizziness.[142]  
In rodents, the SR-BI-mediated selective uptake of HDL cholesterol 
provides a major supply of cholesterol for GC production under stress.[118, 143-
147] A normal maximum corticosterone production upon ACTH stimulation can 
be observed in the LDL receptor knockout mice indicating that the LDL receptor 
is not necessary for acute adrenal steroidogenesis.[148, 149] In contrast, mice 
deficient in ApoA-I, the major HDL ligand for SR-BI, show a blunted 
corticosterone response to ACTH stimulation [112] and lecithin-cholesterol 
acyltransferase (LCAT) deficient mice which have decreased plasma HDL levels 
also present a diminished corticosterone response to ACTH injection or LPS 
exposure[150]. These studies demonstrate the importance of HDL as cholesterol 
donor for the synthesis of GC in adrenal under stress. In this case, SR-BI, as the 
only receptor that mediates the adrenal uptake of cholesteryl esters from HDL in 
mice [151], is critical for GC synthesis under stress.  
1.3.4 SR-BI and sepsis 
SR-BI is important in preventing septic death. Our group first reported a 
protective role of SR-BI in sepsis induced by LPS [152] or by cecal ligation and 
puncture (CLP) [110]. SR-BI-deficient mice display an increased susceptibility to 
death in LPS-induced endotoxemia and CLP-induced sepsis. A sublethal-dose of 
LPS in wild type mice can cause a mortality of 90 % in SR-BI-deficient mice.[152] 
CLP that causes a 20 % fatality in wild type mice can lead to a 100 % fatality in 
SR-BI-deficient mice.[110] SR-BI can protect against septic death through many 
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mechanisms. A significant suppression of tyrosine-nitrated protein formation by 
SR-BI which prevents NO-induced cytotoxicity may contribute to the ability of SR-
BI to protect against LPS-induced death.[152] SR-BI in the adrenal mediates the 
uptake of cholesterol for the production of iGC in sepsis, which is likely to play an 
essential role in preventing septic death given the potent anti-inflammatory 
effects of GC.[109, 110] SR-BI-deficient mice present no iGC production in 
endotoxemia or CLP. Supplementation of corticosterone by drinking water 
restored survival of SR-BI-deficient mice in LPS-induced endotoxemia [109], 
though supplementation of corticosterone in the same way failed to increase the 
survival rate of SR-BI-deficient mice in CLP-induced sepsis [110]. In addition, 
macrophage SR-BI is important for controlling the inflammatory response. 
Macrophage SR-BI can suppress the macrophage production of pro-
inflammatory cytokines by inhibiting TLR4-mediated NF-κB activation. [110] The 
regulation of macrophage pro-inflammatory production by SR-BI also involves 
JNK and p38 cell signaling pathways.[153] This inhibitory effect of SR-BI protects 
against septic death as indicated by that over-expression of SR-BIC323G (a 
mutant SR-BI lacking activity for GC production but capable of suppressing TLR-
4-NF-κB signaling) in SR-BI-deficient mice significantly improves their survival in 
CLP.[110] SR-BI in the liver is also a critical protective factor in sepsis by 
mediating LPS clearance. ScarbII179N mice, a mouse model specifically deficient 
in hepatic SR-BI, show a higher mortality than the wild type mice.[154] Therefore, 
SR-BI protects the animals from septic death through multiple mechanisms as 
shown in Figure 1.8.  
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Figure 1.8 SR-BI plays multiple functions in preventing septic death.    
SR-BI knockout mice show increased susceptibility to septic death. A number of possible 
mechanisms may contribute to the protective effects of SR-BI in sepsis: (1) SR-BI 
protects against NO-induced cytotoxicity (upper left), which prevents tissue damage; (2) 
Adrenal SR-BI mediates the uptake of HDL cholesterol ester to provide cholesterol for 
the synthesis of iGC, which keeps inflammatory responses under control; (3) 
Macrophage SR-BI inhibits LPS-induced inflammatory signaling involving TLR4, JNK, 
p38 and NF-κB pathways (bottom right), which alleviates inflammatory response. (4) 
Hepatic SR-BI mediates the clearance of LPS and thus attenuates the endotoxemia in 
sepsis.[155]  
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1.4 Statement of the problem 
1.4.1 Adrenal insufficiency in sepsis 
Adrenal insufficiency (AI) is indicated by the incapability of adrenal to 
produce cortisol and has been reported in association with septic shock.[156-158] 
The secretion failure of the adrenal glands was first implicated as a factor in the 
pathogenesis of circulatory shock associated with infection after the original 
report of Waterhouse and Friderichsen.[159] These observations emphasized 
that the functional integrity of the HPA axis is essential to survival in severe 
insults. Several decades later, variations in adrenocortical responsiveness in 
septic patients were observed as indicated by the different plasma cortisol 
response to synthetic ACTH.[156] In a study of 32 septic shock patients, the 
patients with poor plasma cortisol response to ACTH all died.[158]  
However, the definition of adrenal insufficiency in sepsis has not been well 
defined. The reported range of serum cortisol in sepsis has varied widely, which 
was probably due to different degree of stress that the enrolled subjects had, the 
type of infection, length of time in shock, and the blood pressure at the time of 
blood sampling.[156, 160-162] Of note, the increase in cortisol levels not only is 
due to the activation of the HPA axis but also partly results from decreased 
cortisol extraction from the blood, decreased binding to CBG, and an increase in 
the half-life of cortisol.[163, 164] Some reports stated that absolute AI is 
uncommon in critically ill patients, but incidence depends on criteria used to 
define it.[158, 163, 165, 166] In addition, the optimal range for serum cortisol 
levels in severe sepsis remains unclear. Therefore, the concept of relative AI 
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then emerged. In relative AI, the cortisol level, despite being normal or high, is 
still considered to be inadequate for the current physiologic stress, and the 
patient may be unable to respond to any additional stress.[158, 167] Thus, 
relative AI is currently defined as an inadequate response to exogenous ACTH. 
Unfortunately, the methods and criteria to diagnose AI or relative AI in critical 
illness or sepsis have not been well defined or standardized. Investigators have 
used a lack of increase in plasma cortisol in response to ACTH [158, 165, 167], 
or an inappropriately low cortisol level during critical illness/septic shock [160, 
168], or both [156, 169] to diagnose AI. Meanwhile, the lower end of serum 
cortisol used to diagnose AI in critical illness has ranged from less than 12.5 
µg/ml to 25 µg/ml.[160, 165, 168-171] These factors overall led to the reported 
incidence of AI varying from 1.5% to 54%.[156, 158, 160, 167-169] 
1.4.2 The use of GC in sepsis 
The use of GC in the therapy of sepsis has been controversial for many 
decades.[172] Early in 1970s, the safety and efficacy of GC in the treatment of 
septic shock was investigated, finding that administration of dexamethasone or 
methylprednisolone decreased the mortality of septic patients.[173, 174] After 
this study, a short course of high-dose GC became an accepted therapy. 
However, subsequent studies did not confirm a survival benefit with this regimen 
and suggested an increase in mortality which is related to secondary 
infection.[175-179] In the 1990s, interest was renewed with the observation of 
HPA axis dysfunction in patients with septic shock.[165, 169, 180] Later, the 
investigators used lower doses of hydrocortisone (200 to 300 mg per day) and 
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found that the low-dose GC therapy decreased the duration of shock in septic 
patients.[181, 182] These studies prompted subsequent larger randomized trials. 
In a multicenter double-blind French trial, Annane et al. revealed that 7-d 
administration of hydrocortisone (50 mg intravenously every six hours) plus 
fludrocortisone (50 mcg enterally once a day) within eight hours of the onset of 
septic shock reduced 28-day mortality by 10% in patients with inadequate 
adrenal reserve (non-responders, maximum cortisol increase of ≤9 mcg/dl upon 
a high-dose (250 mcg) ACTH stimulation test), but made no difference to the 
survival of septic patients with adequate adrenal reverse (responders).[183] 
Following this study, the association between GC therapy and improved mortality 
in sepsis was supported by two subsequent meta-analyses.[184, 185] Then the 
use of low-dose corticosteroids was incorporated into the 2004 surviving Sepsis 
Campaign guidelines, recommending the use of GC for patients with septic 
shock who require vasopressor treatment despite adequate fluid resuscitation. 
Yet, the Corticosteroid Therapy of Septic Shock (CORTICUS), a large 
multicenter double-blind trial, revealed that hydrocortisone (50 mg) every six 
hours for five days can lead to a significantly faster reversal of shock (3.3 versus 
5.8 days in the placebo group) but an increased incidence of new infection and 
non-improved 28-day mortality (35 versus 32 percent in the placebo group) in 
both the responders and the non-responders to the ACTH stimulation.[186] In 
comparing CORTICUS with the French trial, there are important methodological 
differences, especially the characterization of patients including the sources of 
infection, sepsis severity and administration time, etc. [187, 188], which may in 
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part explain the contradiction between their findings. (Table 1.3)  At least, the 
time to initiate GC supplementation seems significantly matters the outcome. A 
study of 178 septic shock patients showed that the mortality rates increased 
significantly with increasing quintiles of time to initiation of low-dose corticosteroid 
therapy, as the early therapy group (administered within 6 hours after the onset 
of septic shock, n = 66) had a 37% lower mortality rate than the late therapy 
group (administered more than 6 hours after the onset of septic shock, n = 112; 
32% versus 51%, p= 0.013).[189]  
Table 1.3 Comparison of French trial and CORTICUS 
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The different results in the relative adrenal insufficiency subgroups 
between the French trial and CORTICUS resulted in new recommendations for 
steroid use in the more recent Surviving Sepsis Campaign guidelines that 
suggest steroid use only in adult patients in septic shock who are poorly 
responsive to fluid resuscitation and vasopressor therapy. However, trials 
following these recommendations have not shown benefits of steroid use in 
sepsis. The Surviving Sepsis Campaign included a large observational database 
of 17,847 patients who met eligibility criteria for low-dose systemic corticosteroids 
(hydrocortisone 50 mg intravenously every six hours or 100 mg every eight hours) 
following the guideline. The results from this campaign showed that the adjusted 
hospital mortality was significantly higher in patients who received low-dose 
steroids compared to those who did not.[190] A prospective, multicenter 
observational study reevaluated the Survival Sepsis Campaign guidelines 
recommendations in steroid use and reported that low-dose steroid had no 
benefits on the hospital mortality.[191] More recent international PROGRESS 
(PROmoting Global Research Excellence in Severe Sepsis) cohort study of 
10,925 severe sepsis patients revealed that the hospital mortality in the low dose 
corticosteroid (LDC, equivalent or lesser potency to hydrocortisone 50 mg/6 
hourly plus 50 μg 9-alpha-fludrocortisone) group was higher than the control 
group without LDC treatment.[192] Thus, it can be seen that the use of GC in 
sepsis is still controversial and a better understanding of its function during 
sepsis is needed to use GC more effectively in the treatment of sepsis.  
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1.4.3 Animal models to study GC in sepsis 
1.4.3.1 Previous approaches to study GC function are not feasible to study 
iGC in sepsis. 
Before the current study, two different approaches have been used to 
investigate GC function: removal of endogenous GC (by adrenalectomy or GC-
receptor antagonists) or administration of exogenous GC. However, these 
approaches are not feasible to study iGC in sepsis.  
The approaches of adrenalectomy and GC-receptor antagonist, which 
remove both basal GC and iGC, are not feasible to specifically investigate the 
role of iGC in sepsis. Previous studies have revealed that endogenous basal GC 
has a role in regulating the homeostasis of metabolism, immune functions and 
behavior under basal condition.[193, 194] Our preliminary data have shown that 
survival sepsis is accompanied by the maintenance of basal GC (Figure 1.9). 
Therefore, considering the importance of basal GC in organismal homeostasis 
and a potential role in sepsis, an approach that specifically eliminates the 
production of iGC is needed to study the functions of iGC in sepsis.  
Also, exogenous GC administration is not feasible to study iGC in sepsis. 
For one thing, synthetic GC is different from endogenous GC in terms of the half-
life and potency [195]. For another, administration of natural GC does not restore 
the function of endogenous GC in GC-eliminated animals [196], indicating a 
different action of endogenous natural GC and exogenously supplemented 
natural GC. Therefore, GC supplementation is not a good approach to 
investigate the role of iGC in sepsis.  
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Figure 1.9 Plasma baseline GC is maintained in survival sepsis in mice.  
B6 mice were subjected to a sublethal insult of CLP (21-guage, half ligation). Plasma 
corticosterone concentrations were evaluated at designated time points. Data represent 
mean ± SEM. (n=7)  
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1.4.3.2 SR-BI-/- mice as a model of adrenal insufficiency  
Due to the importance of SR-BI-mediated delivery of HDL cholesterol in 
iGC production, SR-BI knockout (SR-BI-/-) mice display adrenal insufficiency 
under stress. Overnight fasting (approximately 16 h) stimulates the plasma level 
of corticosterone by 2-fold in wild-type mice but has no effect on plasma 
corticosterone levels in SR-BI-/- mice.[197] SR-BI-/- mice also cannot generate 
iGC in LPS-induced endotoxemia [109] or in cecal ligation and puncture (CLP)-
induced sepsis [110]. Importantly, the plasma corticosterone levels under the 
basal conditions in SR-BI-/- mice are in normal range.[110] Therefore, SR-BI-/- 
mice can be used as an animal model of adrenal insufficiency. 
1.4.3.3 Adrenal-specific SR-BI-/- mice as a model to study iGC in sepsis 
Although the SR-BI-/- mouse is a good model of adrenal insufficiency, it is 
not perfect for the investigation of iGC in sepsis due to its abnormalities in other 
aspects such as dyslipidemia and impaired macrophage function.[155] In this 
regard, the adrenal-specific SR-BI-deficient (adrenal-specific SR-BI-/-) mouse 
model is preferred to investigate the role of iGC in sepsis. Compared to previous 
approaches, this model has a normal range of basal plasma GC concentration. 
Compared to SR-BI-/- mice, this model has normal SR-BI expression in other 
tissue and organs and is free of SR-BI deficiency-induced abnormalities other 
than the lack of iGC. The adrenal-specific SR-BI-/- mouse model has been 
reported previously. Using the technique of adrenal transplantation, Hoekstra M 
et al. generated adrenal-specific SR-BI-/- mice to study the role of GC in lipid 
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metabolism.[198] They have shown that the adrenal-specific deficiency of SR-BI 
leads to an impaired iGC production under a mild stress, such as fasting.  
1.5 Hypothesis and experimental design 
In the current project, we aim to elucidate two issues (1) the role of iGC in 
sepsis and (2) the effects of GC supplementation on survival in sepsis. We 
hypothesized that (1) the SR-BI-regulated endogenous iGC is essential for 
survival in sepsis and (2) GC supplementation benefits the individuals with 
adrenal insufficiency in sepsis but not those without adrenal insufficiency.  
To study the role of iGC in sepsis, we first characterized the phenotypes of 
the adrenal-specific SR-BI-/- mice in terms of the production of corticosterone 
after CLP, the lipoprotein profile and the complete blood count and verified that 
the adrenal-specific SR-BI-/- mice can serve as a good model to study iGC in 
sepsis. Next, in order to elucidate the importance of iGC in sepsis, we analyzed 
the survival rate, the organ damages of the liver, lung and kidneys and the 
production of TNF-α, IL-6, NOx and IL-10 in the adrenal-specific SR-BI-/- mice 
under CLP. In addition, to see if iGC exerts immunosuppressive effects in sepsis, 
we analyzed the phagocytic activity of phagocytes in the blood and spleen as 
well as the activation and apoptosis of lymphocytes in the spleen in the adrenal-
specific SR-BI-/- mice in CLP. (Figure 1.10A) 
To study the effects of GC supplementation on survival in sepsis, we first 
transplanted SR-BI+/+ adrenal to SR-BI-/- mice to see if supplementation of 
endogenous GC can improve the survival rate of adrenal insufficient mice in 
CLP-induced sepsis. Then we exogenously supplemented low-dose GC to SR-
47 
 
BI-/- mice after CLP to see if exogenous GC can benefit the survival of adrenal 
insufficient mice in sepsis. We also supplemented low-dose GC to SR-BI+/+ mice 
after CLP to test our hypothesis that GC supplementation is not beneficial to the 
mice without adrenal insufficiency in sepsis. In addition, we used a “two-hit” 
model of secondary infection in sepsis to study if GC supplementation also 
benefits the survival of adrenal insufficient mice in the secondary infection in 
sepsis. (Figure1.10B) 
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Figure 1.10 Experimental design for this project.  
(A) The role of iGC in sepsis was investigated using the adrenal-specific SR-BI-/- mice 
which was generated by adrenal transplantation. Sepsis was induced by cecal ligation 
and puncture. The GC production, survival rate, organ damages, cytokine levels, 
phagocytosis and lymphocyte activation and apoptosis in CLP were evaluated. (B) The 
effects of GC supplementation on survival in CLP-induced sepsis were studied by (1) 
supplementing endogenous GC through transplanting SR-BI+/+ adrenal to SR-BI-/- mice 
and by (2) administrating exogenous a GC cocktail to SR-BI-/- mice. SR-BI+/+ mice were 
also administrated with the GC cocktail to demonstrate the effects of GC 
supplementation on the survival of individuals without adrenal insufficiency in sepsis. (3) 
A “two-hit” model was used to evaluate the effects of GC supplementation on the 
survival of SR-BI-/- mice in the secondary infection in sepsis.
Copyright © Junting Ai 2014 
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Chapter 2 Materials and methods 
2.1 Material  
2.1.1 Mice  
SR-BI+/− (B6;129S2-Srb1tm1Kri/J) mice were from the Jackson Laboratory. 
SR-BI-/- mice were generated by breeding SR-BI+/− mice and using the littermates. 
Mice were kept and bred in a temperature-controlled room with 12 h light and 12 
h dark diurnal cycle at the animal facility of the University of Kentucky. They were 
housed in filter-topped cages and were fed a standard laboratory chow and water 
ad libitum. Animal care and experiments were approved by the Institutional 
Animal Care and Use Committee of the University of Kentucky. All procedures 
involving with this strain of mice followed the IACUC protocol # 2012-0975. 
2.1.2 Reagents, kits and materials 
The regents, kits and materials used in this project are listed in Table 2.1. 
Table 2.1 List of reagents, kits and materials and their providers 
Chemical/Reagent/Kit                                              Provider (Cat#) 
UltraPureTM  Agarose                                                    Invitrogen  
BSA (bovine serum albumin)                                       Sigma-Aldrich 
Corticosterone EIA kit                                                 Cayman Chemical  
Corticosterone: HBC complex                                      Sigma-Aldrich 
Cholesterol E                                                               Wako Diagnostics  
Ready-SET-Go!® ELISA sets                                        eBioscience                                
 
 
Dulbecco’s Phophsphate Buffered Saline (DPBS)       Gibco  
Continued Table 2.1 
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EDTA (ethylenediaminetetraacetic acid)                       Fisher 
Ethanol                                                                          Fisher 
Escherichia coli (K-12 strain) BioParticles®                   Invitrogen  
Fludrocortisone acetate                                                Sigma-Aldrich 
Formaldehyde                                                               Fisher 
Free Cholesterol E                                                       Wako Diagnostics  
Hydrocortisone- water soluble                                      Sigma-Aldrich 
Hypodermic disposable needles 27G ½”                     EXEL INT® 
Insulin syringe U100 29G ½”                                        BD Biosciences 
In Situ Cell Death Detection Kit                                    Roche  
Isopropyl alcohol                                                           Fisher  
6δ- methylprednisolone                                                Sigma-Aldrich 
Micro-Hematocrit Capillary Tubes                                Fisherbrand® 
MyTaqTM DNA Polymerase 2x                                      Bioline  
NaCl (sodium chloride)                                                 Sigma  
Needles (21- 27 guage)                                                BD Biosciences 
Nitrate/Nitrite Colorimetric Assay Kit                            Cayman Chemical  
NP-40 (nonyl phenoxylpolyethoxylethanol)                  Calbiochem  
Nuclei lysis solution                                                       Promega Corporation  
Protein Precipitation Solution                                        Promega Corporation  
Proteinase K                                                                 Invitrogen (25530015) 
RPMI                                                                            GIBCO®  
Rotating Tail Injector                                                     Braintree scientific, Inc.               
Sterile cell strainer (100 µm)                                         Fisherbrand®     
Syringes (3-5 ml)                                                           BD 
Tris Base                                                                       Fisher  
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2.1.3 Antibodies 
The antibodies used for flow cytometry in this project are listed in Table 
2.2. 
Table 2.2 List of antibodies and their sources and providers 
Antibody                                    Clone                          Provider (Cat#) 
Anti-B220-APC                            RA3-6B2                     Biolegend (103212) 
Anti-CD11b-PerCP-cy5.5            M1/70                          BD (550993) 
Anti-CD11c-APC                         HL3                              BD (550261) 
Anti-CD115- PE                           AFS98                         Biolegend (135506) 
Anti-CD16/32                               93                                Biolegend (101302) 
Anti-CD19-APC                           6D5                              Biolegend (115512) 
Anti-CD3-APC-cy7                     17A2                             Biolegend (100222) 
Anti-CD3-FITC                           17A2                             BD (553138) 
Anti-CD3-PE-cy5                        17A2                             BD (555276) 
Anti-anti-CD45-APC-cy7            30-F11                          Biolegend (103116) 
Anti-anti-CD69-PE                      H1.2F3                         BD (553237) 
Anti-F4/80-PE                             BM8                             eBioscience (12-4801-82) 
Anti-Gr1-APC                              RB6-8C5                      BD (553129) 
Anti-Ly6C-APC                            HK 1.4                         Biolegend (128016) 
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2.1.4 Equipment and software 
The equipments used in this project are listed in Table 2.3. 
Table 2.3 List of antibodies instruments, software and their providers 
Instruments & Software                                        Provider 
AllegraTM 25R Centrifuge                                 Beckman CounterTM 
Anesthesia Machine                                        SurviVet® 
Centrifuge                                                        Eppendorf 
C24 Incubator shaker                                       New Brunswick Scientific 
FlowJo software                                               Tree Star, Inc. 
GenoAmp® PCR System                                  Applied Biosystems 
Image Reader LAS-4000                                 FUJIFILM 
Microscope                                                       Nikon 
Mettler Toledo AB analytical balance               MonoBloc Weighing Technology 
Multi Gauge V3.0 software                               FUJIFILM 
SoftMax® Pro software                                      Molecular Devices’ Industry 
Spectramax® microplate reader                        Molecular Devices’ Industry 
SPSS Statistics                                                 IBM                                                                         
Stomacher                                                         Seward 
Thermalert TH-5                                               Physitemp 
Utility oven                                                         VWR 
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2.2 Methods 
2.2.1 Mouse work 
2.2.1.1 Genotyping of mice 
Genotypes of mice were determined by PCR using tail genomic DNA 
before weaning the pups and were double-checked using genomic DNA from the 
liver tissue after sacrificing the mice. 
 Tail tips were used to genotype the pups before weaning. To prepare the 
genomic DNA, each tail-tip (~0.5 cm) was digested with the digestion buffer (100 
µl lysis buffer + 2 µl 20 mg/ml proteinase K solution, see appendix) in a 55 °C 
water bath for 16-18 h. The digested tails were then centrifuged at a speed of 
2,000 rpm for 5 min at room temperature, and then heated at 98 °C for 10 
minutes to deactivate the proteinase K. 400 µl ddH2O were added to dilute the 
solution. The tubes were then centrifuged 2,000 rpm for 5 min at 4 °C to 
sediment the undigested materials and cooled down on ice. 1 µl supernatant 
(Template) was used for PCR. 
The liver tissue was used to check the genotypes. About 30 mg liver 
tissue was harvested from each mouse. To isolate the genomic DNA from the 
liver, the tissue was cut into small pieces with small scissors, mixed well with 600 
µl digestion buffer (see appendix) by vortex, and digested in a 55 °C water bath 
for 18-20 h. After digestion, 200 µl Protein Precipitation Solution was added to 
each tube. And the tubes were vortexed and then put on ice for 5 min to allow the 
protein to precipitate and then centrifuged 12,000 rpm for 5 min at 4 °C. The 
supernatant was mixed with isopropanol at a ratio of 1:1. After DNA was 
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separated out, the tubes were centrifuged 12,000 rpm, 1 min at 4 °C and the 
supernatant was discarded. The DNA pellet was washed with 70 % ethanol and 
finally dissolved in 400 µl ddH2O. 1 µl DNA template was used for PCR.  
The primers and reaction system are shown below: 
Primers [199]:  
        AB2: 5’-GAT GGG ACA TGG GAC ACG AAG CCA TTC T-3’ 
        AB3: 5’-TCT GTC TCC GTC TCC TTC AGG TCC TGA-3’  
Reaction system: 
        ddH2O                           7 µl 
        Taq Red Mix                 10 µl 
        10 µM AB2 primer         1 µl 
        10 µM AB3 primer         1 µl 
        Template                       1 µl 
Setup of genotyping PCR reaction 
Enzyme activation                                       95 °C               5 min 
Denaturation                                                94 °C              30 s 
Annealing                    35 cycles                  58 °C              30 s 
Extension                                                     72 °C              2 min 
Elongation                                                    72 °C              10 min 
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PCR products were analyzed on 1.5 % agarose gels, 100 voltages for 30 
min. Pictures were taken using the LAS-4000 Imaging System and the Multi 
Gauge V3.0 software. (Figure 2.1) 
 
Figure 2.1 Genotyping for SR-BI alleles.  
PCR system for SR-BI genotyping was set up as described in 2.2.1. 15 µl PCR products 
were resolved in a 1.5% agarose gel under 100 voltages for 30 min.   
 
2.2.1.2 Adrenal transplantation (ADR-T) Surgery  
Adrenalectomy and subsequent adrenal transplantation were performed 
as previously described by Karpac et al.[200] At postnatal day 8, the pups from 
SR-BI+/- breeders were genotyped using genomic DNA isolated from tails. At day 
9, the pups were euthanized by CO2 to harvest their adrenal glands right before 
the transplantation.  
Immediately after the donor adrenal glands were isolated, recipient mice 
(8-10 weeks) were anesthetized by 5 % isoflurane inhalation and maintained with 
2.5% isoflurane during the surgery. After anesthetization, the mouse was 
bilaterally adrenalectomized by a pair of surgery tweezers through a dorsal 
midline skin incision and lateral retroperitoneal incisions. The left incision was 
sutured right after removal of the left adrenal gland. Then the right kidney was 
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exposed, and one donor adrenal gland was put under the right kidney capsule 
through a slit in the kidney capsule made by the tweezers. Then the right kidney 
was returned; and the right incision and the skin were sutured. The mouse was 
kept warm on a heater mat until it waked up from narcosis. The mice were given 
0.9% NaCl and normal water ad libitum. Then they were housed separately for 
one week and four mice per cage in the following weeks. The mice were used for 
experiments 6 weeks after the surgery. (Figure 2.2)  
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Figure 2.2 The adrenal transplantation surgery  
(A) After anesthetization under isoflurane inhalation, the surgery area is shaved, cleaned 
and disinfected with iodine and 70 % ethanol. Then (B) a dorsal midline skin incision is 
made and (C and D) bilateral adrenal glands are removed by lateral retroperitoneal 
incisions. (E) The left incision is sutured right after the removal of left adrenal gland. 
Then (F) the right kidney is exposed. Subsequently, (G) a slit in the adrenal capsule is 
made by tweezers and (H) one donor adrenal gland from a 9-d pup is put under the right 
kidney capsule. (I)The kidney with the transplanted adrenal is put back and the right 
incision is sutured. Finally, (J) the dorsal skin incision is sutured. The mice are kept 
warm on a heater mat until they wake up from narcosis.  
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2.2.1.3 Cecal Ligation and Puncture (CLP) sepsis model 
The cecal ligation and puncture (CLP) was used to induce septic 
conditions in mice. This model has many pathophysiological similarities to the 
clinical situation where bowel perforation-induced peritonitis results from an 
infection that is caused by mixed intestinal flora. The CLP model is one of the 
most widely used models of sepsis and is considered as a golden model for 
sepsis study. This model fulfills the human condition that is clinically relevant. 
Like in humans, mice that undergo CLP with fluid resuscitation show the first 
(early) hyperdynamic phase that in time progresses to the second (late) 
hypodynamic phase.[201] In addition, the CLP-induced sepsis shows a cytokine 
profile similar to human sepsis.[202, 203] 
For the CLP surgery, the mouse was anesthetized by isoflurane inhalation. 
The abdominal hairs were shaved, and the area was disinfected with iodine 
followed by 70% ethanol. The abdominal cavity was opened via a midline 
laparotomy incision of about 1 cm in an aseptic fashion and the cecum was 
exposed. The cecum was ligated at a designated distance from the ileocecal 
valve. The ligated cecum was punctured twice with a needle. Next, sufficient 
pressure was applied to the cecum to extrude a single droplet of fecal material 
from each puncture site. The abdomen was closed, and mouse was resuscitated 
with 1 ml of PBS by i.p. injection. The mouse was kept warm on a heater mat 
until it woke up from narcosis. (Figure 2.3) 
In the CLP model, the grade of severity has a direct impact on the 
percentage of survival. The severity of sepsis can be modified by the length of 
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the ligation, the thickness of the needle and the number of punctures, which 
could be controlled by the animal surgeon.[204, 205] A substantial variability in 
the CLP results could be induced by the mouse strain [206, 207], sex [208] and 
age [209] of the animal as well. Thus, we used sex and age-matched mice and 
adjusted the severity with different ligation and puncture conditions in our study.  
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Figure 2.3  The cecal ligation and puncture sepsis model.  
(A) After anesthetization, the abdominal hairs are shaved and the area is disinfected.  (B) 
The abdominal cavity is opened via a midline incision of about 1 cm in an aseptic fashion. 
Then (C) The cecum is exposed and (D) is ligated at a designated distance to the 
ileocecal valve, carefully not to disturb the ileocecal flow. (E) The ligated cecum is 
punctured once “through-and-though” with a needle and (F) sufficient pressure is applied 
to the cecum to extrude a single droplet of fecal material from each puncture site. At last, 
(G) the cecum is put back in to the abdomen cavity and (H) the abdomen is closed. (I) 
the mouse is given 1 ml of PBS by i.p. injection for fluid resuscitation and is monitored 
regularly.   
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2.2.1.4 In vivo delivery of bacteria 
FITC labeled-Escherichia coli (E. coli, K-12 strain) were used for the in 
vivo study of bacteriae delivery. FITC-E.coli powder was reconstituted in a vial at 
20 mg/ml in sterile PBS with 2 mM sodium azide as the stock. To prepare the 
bacteria for injection, the designated amount of FITC-E.coli were pipetted out to a 
new sterile 1.5 ml EP tube, washed with sterile 1ml PBS by centrifuging at a 
speed of 8,000 rpm at 4 °C for 5 min and suspended in sterile PBS to a final 
concentration of 1x109/ ml. Then the bacteria were killed by heating at 75 ⁰C for 
20 min. 100 µl final E.coli solution was injected to the mouse by tail vein injection.   
2.2.1.5 GC supplementation 
For GC supplementation to CLP mice, a cocktail containing 100 µg 
hydrocortisone, 25 ng fludrocortisone acetate and 20 µg 6δ-methylprednisolone 
was injected to the mouse right after the surgery. Water-soluble hydrocortisone 
was dissolved in PBS at a concentration of 9.2 mg/ml (equivalent of 1 mg/ml 
hydrocortisone), and 100 μl/mouse hydrocortisone solution was injected 
intraperitoneally. Fludrocortisone acetate was dissolved in oil at a concentration 
of 2.5 mg/ml and diluted to a final concentration of 500 ng/ml. 6δ-
methylprednisolone was dissolved in oil at a concentration of 2 mg/ml and diluted 
to a final concentration of 400 µg/ml. A mix of fludrocortisone and 
methyprodinisolone was injected 50 μl/ mouse subcutaneously. For 
corticosterone administration, corticosterone: HBS was dissolved in PBS and 200 
μg/mouse corticosterone was injected intraperitoneally. For GC supplementation 
to mice with secondary infection, a cocktail containing a half dose (50 µg 
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hydrocortisone, 12.5 ng fludrocortisone acetate and 10 µg 6δ-methylprednisolone) 
was injected after inoculation by the same approach.  
2.2.1.6 Body temperature measurement 
Body temperature was measured in the adrenal-specific SR-BI-/- mice and 
the control mice via rectum. Briefly, the mice were held vertically and the rectal 
temperature was monitored by the TH-5 Thermalert Monitoring Instrument. The 
rectal probe was cleaned by 75% ethanol between measurements. 
2.2.1.7 Blood collection 
Blood was collected through abdominal arterial puncture or tail bleeding. 
For the abdominal arterial puncture, the mice were anesthetized by isoflurane 
inhalation to collect blood through abdominal arterial puncture. 3 ml syringe and 
27-gauge needles were rinsed with 0.5 M EDTA and 20 μl 0.5 M EDTA was 
added to each 1.5 ml EP tube for blood collection to prevent coagulation. For the 
tail bleeding, the blood was collected through a tail cut using a microhematocrit 
capillary tube and pipetted out to a collecting EP tube. The collected blood was 
centrifuged immediately at 12,000 rpm, 4 °C for 10 min. The plasma was pipetted 
out and stored at -80 °C for use.  
2.2.1.8 Lung wet-to-dry (W/D) ratio 
 Lung W/D ratios were detected as a parameter of pulmonary edema. 
Immediately after the mice were killed, the lungs were carefully dissected from 
large airways, heart and mediastinal structures. Excess fluid was absorbed with 
soft tissue paper. The lungs were weighed immediately after being isolated (wet 
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weight) and again after 96 h at 65°C in a drying oven (dry weight) for 
computation of the W/D ratio dividing the wet weight by the dry weight.[210] 
2.2.2 Histology 
Immediately after mice were sacrificed, the kidneys with or without the 
transplanted adrenal glands were carefully removed and fixed in 10% formalin in 
PBS for 24 h. Specimens were then embedded in paraffin. A series of 5-μm-thick 
sections were cut and stained with hematoxylin and eosin (H&E) by the Histology 
Core in the Markey Cancer Center. Pictures were taken using the Nikon 
Microscope and Nikon capture software. 
2.2.3 Biochemistry and molecular biology  
2.2.3.1 Corticosterone assay 
The concentrations of plasma corticosterone were measured using the 
Corticosteroe EIA kit (Cayman Chemicals) according to the manufacturer’s 
instructions. This assay is a competition based assay in which corticosterone 
competes with corticosterone-acetylcholinesterase (AChE) conjugate 
(Corticosterone Tracer) for binding to a limited number of corticosterone-specific 
sheep antiserum binding sites. AChE hydrolyzes acetylcholine, producing 
thiocholine. The reaction of thiocholine with the detection reagent 5, 5'-dithiobis-
(2-nitrobenzoic acid) (DTNB) produces 5-thio-2-nitrobenzoic acid, which has a 
strong absorbance at 412 nm. Samples were diluted 1/200 to 1/400. 
65 
 
2.2.3.2 Cholesterol assay 
Plasma total and free cholesterol concentrations were measured by kits 
from the Wako Diagnostics. Briefly, it is an enzymatic method involving the 
oxidation of free cholesterol by cholesterol oxidase to ∆4-cholestenone and the 
simultaneous production of hydrogen peroxide. The total amount of cholesterol in 
the test sample is determined by measurement of the absorbance at 600 nm. 
2.2.3.3 Cytokine assay 
The concentrations of plasma TNF-α, IL-6 and IL-10 were measured by 
ELISA kits from the eBioscience. For the TNF-α assay, all samples were diluted 
1/5.  For the IL-6 assay, samples were diluted 1/10 to 1/40. For the IL-10 assay, 
samples were diluted 1/5 to 1/10. 
2.2.3.4 Nitric oxide assay 
Measurement of NO in vivo is difficult because of its short half-life, but 
plasma nitrate/nitrite (NOx), the stable products of NO oxidation, can be 
measured as markers of NO activity.[211, 212] Therefore, the concentrations of 
plasma NOx were measured by the Nitrate/Nitrite Colorimetric Assay Kit 
(Cayman Chemical). This assay is involved with a conversion of nitrate to nitrite 
by nitrate reductase and a further conversion of nitrite into a deep purple azo 
compound, which has a strong absorbance at 540 nm or 550 nm. Samples were 
diluted 1/4 to 1/8. 
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2.2.3.5 Urea nitrogen assay 
Blood urea nitrogen (BUN) raises if kidneys fail to remove urea from the 
body and has been used a marker for the kidney injury.[213] The concentrations 
of BUN were determined by measuring the urea nitrogen in the plasma using the 
QuantiChromTM Urea Assay Kit with a quantitative colormetritc method.  
2.2.3.6 Alanine aminotransferase assay 
Alanine aminotransferase (ALT) is mainly in the liver and normally kept in 
a low level in the blood. When the liver is damaged, ALT is released into the 
blood stream and therefore increased ALT in the blood is considered as a marker 
for liver damage. To evaluate the liver damage in CLP mice, the concentrations 
of plasma ALT were measured by the ALT reagent from BQ kits. It is a 
colorimetric method. The ALT catalyzes L-alanine and a-ketoglutarate to form 
pyruvate and glutamate. The pyruvate then reacts with 2, 4-
dinitrophemylphdrazine (2, 4-DNPH-one), which can be measured at 505 nm 
after being dissolved by the addition of sodium hydroxide. 
2.2.3.7 Lipoprotein profile analysis  
Plasma lipoprotein profile was analyzed by FPLC as described 
previously.[214] Briefly, plasma (50 μl) was resolved by gel filtration 
chromatography using an FPLC system equipped with a Superose 6 column (GE 
Healthcare). The column was eluted at a flow rate of 0.5 ml/min in buffer 
containing 150 mm NaCl, 10 mm Tris-HCl (pH 7.4), and 0.01% sodium azide, 
and 0.5 ml/fraction was collected. 100 μl of sample was mixed with an equal 
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volume of 2× assay reagent (Wako Chemicals) to determine the cholesterol 
content of fractions.  
2.2.4 Primary cell analysis 
2.2.4.1 Preparation of single cell suspensions 
Single cell suspensions were prepared from freshly dissected spleens 
following standard procedures. Briefly, spleens were weighed immediately after 
dissection and 70-100 mg of a spleen was used. The spleen tissue for 
homogenization was put into a stomacher bag (Seward) containing 10 ml RPMI 
1640-5 (see appendix) and disrupted using the Stomacher 80 (Seward) at the 
high speed for 2 min. The cell suspension was transferred to a 50 ml centrifuge 
tube (BD Biosciences) through a 100 µm cell strainer (BD Biosciences) by a 10 
ml pipette. 5 ml of RPMI 1640-5 was added to wash the stomacher bag in order 
to transfer the cells thoroughly. Then the cell suspension was centrifuged at 
1,500 rpm for 5 min at 4 ˚C. The supernatant was discarded and the cells were 
incubated with 5 ml of ACK lysis buffer (see appendix) at room temperature for 5 
min to deplete erythrocytes. The lysis of erythrocytes was ceased by adding 10 
ml of Dulbecco’s Phophsphate Buffered Saline (DPBS). 100 µl of the cell 
suspension after lysis was diluted 1/10 with RPMI 1640-5 and counted using a 
counting chamber. The cells were centrifuged at 1,500 rpm for 5 min at 4 °C, 
washed again with DPBS and finally suspended in 5 ml RPMI 1640-5.  
Blood was collected from mouse by abdominal arterial puncture as 
described earlier. 300 µl of anti-clotted blood was added into 5 ml of ACK lysis 
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buffer in a 50 ml centrifuge tube to remove erythrocytes. After incubation for 5 
min, 45 ml of DPBS was added to cease lysis and the cells were centrifuged at 
1,500 rpm for 5 min at 4˚C. The pellet was resuspended with 1 ml of RPMI 1640-
5. 10 µl of the cell suspension was directly counted using a counting chamber. 
2.2.4.2 Fluorescence-activated cell sorting (FACS) analysis 
5x105 cells were used for the surface marker antibody staining. The single 
cell solution was centrifuged at 2,000 rpm for 5 min at 4˚C and the supernatant 
medium was removed. The cells were resuspended with 30 µl FACS staining 
buffer (see appendix) containing 0.25 µg of anti-mouse CD16/CD32 and 
incubated for 10 min at 4˚C to block Fc receptors. Then 20 µl FACS staining 
buffer containing fluorescence-labeled antibodies (0.125 µg per antibody) were 
added and the cells were further incubated at 4˚C for 30 min. After the incubation, 
the cells were washed twice with 500 µl of FACS staining buffer and suspended 
in 250 µl FACS staining buffer. Finally the stained cells were analyzed with 
FACSCalibur or LSRII flow cytometer (BD Biosciences). The generated data 
were analyzed with FlowJo software. 
2.2.4.3 TUNEL assay  
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) is 
a wildly used method for cell apoptosis analysis by detecting DNA 
fragmentation.[215] The rationale for this assay is that the terminal 
deoxynucleotidyl transferase (TdT) can identify the nicks in DNA and thus 
catalyze the addition of dUTPs that are secondarily labeled. In this study, TUNEL 
incorporation detection was conducted by using the in situ cell death detection kit 
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following the manufacturer’s protocol (Roche). Briefly, cells were stained with cell 
surface marker antibodies as described in 2.2.4.2, and then incubated with 100 µl 
of BD Cytofix/Cytoperm solution (BD Biosciences) for 20 min at room 
temperature. After the incubation, the cells were washed twice with 1x BD 
Perm/Wash buffer (BD Biosciences) and incubated with 50 µl of TUNEL reaction 
mixture (Roche) for 1 hour at 37˚C. Finally the cells were washed twice with 
FACS staining buffer, suspended in 500 µl of FACS staining buffer and analyzed 
with LSRII flow cytometer.  
2.2.5 Microbiology 
The strain Pseudomonas aeruginosa (ATCC 27853) was utilized in the 
secondary infection model. All procedures involving with this strain of bacteria 
followed the biosafety protocol #B11-1792-M3. 
2.2.5.1 Preparation of bacteria stock 
Bacteria were propagated immediately following the instructions of ATCC 
after arriving. Briefly, the bacteria were rehydrated with 1 ml sterile tryptic soy 
broth (TSB) and then aseptically transferred into 5 ml sterile TSB broth and 
several drops of the suspension were used to inoculate a sterile TSB agar plate. 
After incubation at 37 °C for 24 h, a single colony was used for further 
propagation in a flask containing 400 ml sterile broth by incubating at 37 °C for 
24 h with shaking. Then the bacteria in the broth were then divided into 40 ml/ 
tube and centrifuged at 5,000 rpm, 4°C for 20 min. The supernatant was 
discarded and the bacteriae were resuspended with sterile 7 ml PBS. Then 3 ml 
sterile 50 % glycerol was added to each tube. The bacteria suspension was 
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finally mixed thoroughly and divided into sterile 1.5 ml EP tubes with 1 ml/ tube. A 
drip of the suspension was used to inoculate the agar plates to count the colony-
forming unit (CFU).  
2.2.5.2 Inoculation of animals 
Stock bacterial solution was warmed at 37 °C in water bath. After 
thoroughly melted, the bacteria were washed once by 1 ml sterile PBS by 
centrifuging at 8,000 rpm, 4°C for 5 min and resuspended in 1 ml sterile PBS. 
The bacterial suspension was diluted to a concentration of 1x109 CFU/ ml for 
inoculation. For inoculation, the mice were anesthetized under isoflurane 
inhalation and held vertically in a “heads-up” position. Using an Eppendorf pipette 
that was calibrated, 50 µl of the bacteria suspension (1x109 CFU/ ml) was slowly 
injected intranasally and observed to be aspirated on inhalation. After the 
inoculation, the mice were monitored in a BSL-2 animal room for survival study. 
2.3 Data Analysis 
All the statistical analyses were performed with SPSS Statistics, version 
21 software. For comparison of means, differences in quantitative variables in the 
same group were analyzed by 2-tailed Student's t test. Data from multiple groups 
were analyzed with one-way ANOVA with Tukey post hoc test. All groups 
analyzed conformed to the constraints of parametric analysis. Data were 
presented as means ± S.E.M. Differences in survival rate and survival time were 
analyzed by Kaplan-Meier method with log-rank x2 test. Correlations between 
variables were evaluated by two-tailed Pearson's correlation coefficient value. 
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Data were presented as Pearson’s coefficient (r). P value of <0·05 was 
considered significant.  
Copyright © Junting Ai 2014 
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Chapter 3 The role of SR-BI-regulated iGC in sepsis 
Section 1 Adrenal-specific SR-BI-deficient mice are a good iGC-deficient 
animal model.  
3.1.1 Introduction 
Despite new developments in critical care and sepsis therapy, severe 
sepsis and septic shock are still major healthcare problems.[3, 6, 8] The initial 
inflammatory response to sepsis stimulates the production and release of iGC 
from the adrenal cortex.[92] However, the exact function of iGC in sepsis remains 
unclear due to a lack of good animal model. 
Previous approaches are not feasible to study the role of iGC in sepsis. 
The approaches of adrenalectomy and GC-receptor antagonist, which remove 
both basal GC and iGC, are not feasible to investigate the role of iGC in sepsis 
considering that basal GC is important in regulating the organismal homeostasis 
[193, 194] and is maintained in survival sepsis (preliminary data). In addition, 
studies of exogenous GC may over-simplify the action of endogenous GC.[195] 
Thus a better animal model is needed to investigate the function of endogenous 
iGC in sepsis.  
Mouse specifically deficient in iGC may serve as a good animal model to 
study endogenous iGC in sepsis. SR-BI-/- mice have normal plasma 
corticosterone under basal conditions but cannot produce iGC in sepsis [109, 
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110, 197, 216, 217], therefore they may serve as an adrenal insufficient mouse 
model. However, mice that are specifically deficient in adrenal SR-BI will be a 
more suitable model than SR-BI-/- mice to study iGC in sepsis, because SR-BI-/- 
mice also display abnormalities in other aspects such as dyslipidemia, impaired 
functions of macrophages and attenuated liver uptake of LPS. [155].  
In this section, we characterized adrenal-specific SR-BI-/- mice as a good 
model of iGC deficiency to study the role of iGC in sepsis. We verified that the 
adrenal-specific SR-BI-/- mice have normal basal GC concentration in plasma but 
cannot generate iGC in CLP. We also showed that the transplanted SR-BI-/- 
adrenal grafts can grow with normal structure. In addition, we showed that the 
adrenal-specific SR-BI-/- mice have no difference in the plasma lipoprotein profile 
and blood cell counts compared to the control mice, demonstrating that adrenal-
specific SR-BI-/- mice are a good model to study the role of iGC in sepsis. 
 
3.1.2 Results 
3.1.2.1 Adrenal-specific deficiency of SR-BI does not impair basal GC but 
leads to iGC deficiency in CLP-induced sepsis.  
To generate the mouse specifically lack SR-BI in adrenal, we transplanted 
a donor adrenal gland from 9-day SR-BI-/- pups to 8-10-week-old female SR-BI+/+ 
mice after their own adrenal glands were removed. The control mice were 
generated by transplanting a donor adrenal gland from age-matched SR-BI+/+ 
littermate pups following the same procedure. To verify the success of this model, 
we conducted CLP to these mice and measured their plasma corticosterone 
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levels at the points of CLP 0 h, 4 h and 18 h. As shown in Figure 3.1, at CLP 0 h, 
the adrenal-specific SR-BI-/- mice did not show significant difference in the 
plasma corticosterone concentration compared to the control mice (113.2 ± 21.0 
ng/ml vs. 173.5 ± 36.6 ng/ml, p=0.192), indicating that adrenal-specific deficiency 
of SR-BI does not impair basal GC. At CLP 4 h, the control mice had a 2.4-fold 
increase in plasma corticosterone (Figure 3.1) compared to their basal levels, 
indicating a production of iGC upon CLP. In contrast, the adrenal-specific SR-BI-/- 
mice displayed a 2.3-fold decrease in plasma corticosterone at CLP 4 h 
compared to their basal levels, which was significantly lower than the level in the 
control mice at this point. At CLP 18 h, the plasma corticosterone in the control 
mice was still 80 % higher than their basal level, whereas the plasma 
corticosterone in the adrenal-specific SR-BI-/- mice remained at the basal level 
and was significantly lower than the control mice (114 ± 14.9 ng/ml vs. 311 ± 
26.2 ng/ml, p<0.001). These data demonstrate that the adrenal-specific SR-BI-/- 
mice are completely deficient in iGC in CLP-induced sepsis. 
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Figure 3.1 Adrenal-specific deficiency of SR-BI leads to iGC deficiency in CLP-
induced sepsis.  
Adrenal-transplanted mice were subjected to CLP surgery (21-gauge, half ligation) and 
the plasma was taken at designated time for plasma corticosterone assay. Data 
represent mean ± SEM. (n=6-8 per group). ** p<0.01, *** p<0.001  
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3.1.2.2 Adrenal-specific deficiency of SR-BI does not influence the growth 
of transplanted adrenal grafts. 
On euthanization of the mice, we harvested the kidneys and adrenal 
transplants from the recipient mice for further gross morphological examination 
and histological analysis. As shown in Figure 3.2, both SR-BI+/+ and SR-BI-/- 
adrenal grafts grew under the kidney capsule. Further histological analysis 
showed that both SR-BI+/+ and SR-BI-/- adrenal transplants consisted of adrenal 
cortex surrounding the medulla and the adrenal cortex has clear zona 
glomerulosa, zona fasciculata and zona reticularis (Figure 3.2). These data 
indicate that adrenal-specific deficiency of SR-BI does not influence the growth of 
transplanted adrenal grafts in the recipients. 
77 
 
 
 
Figure 3.2 Transplanted adrenal glands show normal structure.  
Six weeks after adrenal transplantation, the mice were sacrificed and the right kidneys 
with transplanted adrenal glands were harvested for the pictures and histology analysis. 
The left panel shows the appearance of adrenal gland under the kidney capsule (upper) 
and the HE staining of the adrenal glands (lower). The right panel shows the amplified 
HE staining pictures of the transplanted adrenal grafts. ZG, zona glomerulosa; ZF, zona 
fasciculata; ZR, zona reticularis; M, medullary region 
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3.1.2.3 Adrenal-specific deficiency of SR-BI does not influence plasma 
cholesterol concentrations or lipoprotein profiles under basal conditions. 
Since plasma lipoproteins serve as the major source of cholesterol for GC 
synthesis in the adrenal [147, 218] and atherogenic diet-fed adrenal-specific SR-
BI-deficient mice display decreased plasma very-low-density and low-density 
lipoprotein levels [198], we determined the plasma cholesterol concentrations 
and lipoprotein profiles to see whether or not the chow diet-fed adrenal-specific 
SR-BI-/- mice display changes in the lipoproteins. As shown in Figure 3.3A, the 
adrenal-specific SR-BI-/- mice showed comparable concentrations of plasma total 
cholesterol (83.8 ± 1.8 mg/dl vs. 89.3 ± 3.7 mg/dl, p=0.227) and free cholesterol 
(19.4 ± 0.7 mg/dl vs. 20.2 ± 1.6 mg/dl, p=0.661) with the control mice. The FPLC 
analysis also showed no difference in the lipoprotein profile between the adrenal-
specific SR-BI-/- mice and the control mice (Figure 3.3B). These data indicate that 
the adrenal-specific deficiency of SR-BI does not influence the plasma lipoprotein 
levels. 
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Figure 3.3 Adrenal-specific deficiency of SR-BI does not influence plasma 
cholesterol concentrations or lipoprotein profiles.  
Six weeks after adrenal transplantation, the plasma was taken from untreated adrenal-
transplanted mice. (A) Plasma total and free cholesterol concentrations were measured. 
Data present mean ± S.E.M. (n=6) (B) Plasma lipoprotein profile was analyzed by FPLC. 
Data show representative lipoprotein profiles. VLDL, very-low density lipoprotein; LDL, 
low-density lipoprotein; HDL, high-density lipoprotein 
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3.2.1.4 Adrenal-specific deficiency of SR-BI does not influence the blood 
cell counts under basal conditions.  
It  has been reported that adrenalectomized mice have a significant 
increase in the number of mononuclear cells in the blood [219], thus we analyzed 
the complete blood counts in the adrenal-transplanted mice to see if adrenal-
specific SR-BI deficiency also impacts those cells. As indicated in the Table 3.1, 
the adrenal-specific SR-BI-deficient mice showed a normal blood cell profile and 
no significant difference in terms of the number of white blood cells, neutrophils, 
lymphocytes, monocytes and red blood cells compared to the control mice. 
These data demonstrate that the adrenal-specific deficiency of SR-BI does not 
influence the blood cell counts.  
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Table 3.1 Adrenal-specific deficiency of SR-BI does not influence the blood cell 
counts under basal conditions. 
 
Anticoagulant blood harvested from the artery puncture was used for complete blood 
counting. WBC, white blood cell; NE, neutrophil; LY, lymphocyte; MO, monocytes; RBC, 
red blood cell; Hb, hemoglobin; PLT, platelet. n=4 vs. 5 
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3.2.3 Summary 
In this section, we checked the phenotypes of adrenal-specific SR-BI-/- 
mice generated by adrenal transplantation and verified these mice as a good 
animal model to study the role of iGC in sepsis. First, we conducted CLP to the 
adrenal-transplanted mice, showing that the adrenal-specific SR-BI-/- mice have a 
normal level of plasma corticosterone under basal conditions but totally lack iGC 
upon CLP, which indicates that adrenal-specific SR-BI deficiency leads to iGC 
deficiency in sepsis. Then we showed that both SR-BI+/+ and SR-BI-/- adrenal 
grafts grow well and have normal adrenal structure. In addition, because 
changes of plasma lipoproteins have been reported in the atherogenic diet-fed 
adrenal-specific SR-BI-/- mice [198], we measured the plasma cholesterol 
concentrations and lipoprotein profiles to see if adrenal-specific SR-BI deficiency 
influences plasma lipoprotein on a chow-diet feeding. We showed that the 
adrenal-specific SR-BI-/- mice have normal plasma cholesterol concentrations 
and lipoprotein profiles, demonstrating that adrenal-specific deficiency of SR-BI 
does not influence the plasma lipoproteins. Finally, since adrenalectomized mice 
have a significant increase in the number of mononuclear cells in the blood [219], 
we analyzed the complete blood counts in the adrenal-specific SR-BI-/- mice and 
observed no difference in the blood counts between the adrenal-specific SR-BI-/- 
mice and the control mice. Overall, this section demonstrates that adrenal-
specific SR-BI-/- mice are a good model to investigate iGC in sepsis. 
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Section 2 Role of SR-BI-regulated iGC in CLP-induced sepsis. 
3.2.1 Introduction 
The exact function of iGC in sepsis remains unclear due to the lack of a 
good animal model. After characterizing adrenal-specific SR-BI-/- mice as a good 
animal model to investigate iGC in sepsis, we used this model to test our 
hypothesis that iGC is essential for survival in sepsis and investigated the 
functions of iGC in sepsis. 
First, we observed a significantly higher mortality in the adrenal-specific 
SR-BI-/- mice in CLP-induced sepsis compared to the control mice, demonstrating 
that iGC is essential for survival in sepsis. We also detected a higher occurrence 
of low body temperature, an indicator of septic shock, in the adrenal-specific SR-
BI-/- mice than the control mice, indicating that iGC participates in preventing the 
development of septic shock. Then, because multiple organ damage contributes 
to a high mortality in sepsis, we measured the plasma alanine amino 
tranasferase (ALT) level, the lung wet-to-dry (W/D) ratio and blood urea nitrogen 
(BUN), which respectively reflect the damage of liver, lung and kidneys in the 
adrenal-specific SR-BI-/- mice to see if iGC protects organ damage in sepsis. We 
found that iGC has no effect on the liver or lung damage but prevents the kidney 
injury in sepsis. To further understand the mechanism underlying the protective 
effect of iGC in sepsis, we analyzed the production of pro-inflammatory cytokine 
TNF-α and IL-6, pro-inflammatory mediator NO and anti-inflammatory cytokine 
IL-10 in the adrenal-specific SR-BI-/- mice to determine if iGC benefits sepsis 
survival through its anti-inflammatory action. We found that iGC regulates the 
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pro-inflammatory cytokines, particularly exerting an inhibitory effect on IL-6. 
Finally, since GC has been considered as an immunosuppressive agent [101] 
and immunosuppression in sepsis is associated with an increased mortality in the 
late phase of sepsis[52],  we tested whether or not iGC is immunosuppressive in 
sepsis. To assess the effects of iGC on innate immunity, we measured the 
phagocytic activity of phagocytes in the blood and spleen by analyzing the 
phagocytosis of injected fluorescence-labeled E. coli. We found that iGC in 
sepsis increases the phagocytic activity of neutrophils and monocytes in the 
blood. To assess the effects of iGC on adaptive immunity, we quantified the 
activation and apoptosis of lymphocytes in the spleen by staining CD69 and 
TUNEL in the CLP adrenal-specific SR-BI-/- mice and showed that iGC in sepsis 
enhances the activation of T lymphocytes and does not induce more apoptotic 
cells in the spleen. In all, our data in this section reveal that iGC is essential for 
survival in sepsis. It prevents the kidney injury, regulates cytokine production and 
exerts immunomodulatory action in sepsis.  
 
3.2.2 Results 
3.2.2.1 Inducible GC protects against CLP-induced septic death.  
After characterizing adrenal-specific SR-BI-/- mice as an iGC-deficient 
mouse model, we used this model to investigate the effects of iGC in sepsis. First, 
we determined the influence of iGC deficiency on the mortality in sepsis by 
looking at the survival rate of the adrenal-specific SR-BI-/- mice in CLP. As shown 
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in Figure 3.4, CLP induced a 46% fatality in the adrenal-specific SR-BI-/- mice as 
against no fatality in the control mice at CLP 24 h. There was a 62% fatality in the 
adrenal-specific SR-BI-/- mice compared to a 17% fatality in the control mice at 
CLP 48 h. After CLP 48 h,  no more death occurred in the control mice whereas 
the fatality in the adrenal-specific SR-BI-/- mice increased to 71% at CLP 72 h 
and 87% at CLP 120 h. Overall, a 7-day survival rate reached a significant 
difference between these two groups (p<0.001). These data demonstrate that 
iGC is critical for survival in sepsis.  
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Figure 3.4 Inducible GC protects against CLP-induced septic death.  
The adrenalectomized SR-BI+/+ mice transplanted with one SR-BI+/+ or SR-BI-/- adrenal 
gland were subjected to CLP (21-guage, half ligation) 6 weeks after adrenal 
transplantation. The survival was monitored for 7 days. Data are expressed as the 
percentage of mice surviving at the indicated time and analyzed by the log-rank x2 test. 
*** p<0.001  
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3.2.2.2 Inducible GC prevents the development of septic shock. 
Low body temperature (<30°C) is an indicator of septic shock.[220] As 
shown in Figure 3.5, low body temperature was present in 9/10 adrenal-specific 
SR-BI-/- mice but only in 1/6 of the control mice at CLP 18 h. The average body 
temperature in the adrenal-specific SR-BI-/- mice was significantly lower than the 
control mice (24.9 ± 1.6 °C vs. 34.0 ± 2.2 °C, p=0.004; Figure 3.5). These data 
suggest that iGC protects the mice from septic shock. 
 
Figure 3.5 Inducible GC prevents the development of septic shock.  
The SR-BI+/+ mice transplanted with SR-BI+/+ or SR-BI-/- adrenal glands were subjected 
to CLP (21-guage, half ligation) 6 weeks after adrenal transplantation. The body 
temperature was measured at CLP 18 h through rectum. Data represent mean ± S.E.M. 
n= 6 vs. 10 in control versus adrenal specific SR-BI-/- mice respectively, ** p<0.01 
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3.2.2.3 Inducible GC protects against CLP-induced kidney injury in sepsis. 
Multiple organ dysfunctions are a hallmark of severe sepsis, which 
contributes to an increased mortality in sepsis.[3] To understand the mechanism 
by which SR-BI protects against septic death, next we investigated the impact of 
iGC in organ functions by assessing liver, lung and kidney damages in CLP. As 
shown in Figure 3.6A and 3.6B, compared to the control mice, the adrenal-
specific SR-BI-/- mice displayed no difference in the plasma ALT level and the 
lung W/D ratio after CLP, indicating that iGC may not protect liver or lung injury in 
sepsis. However, measurements of plasma BUN concentrations showed a 
significant difference between the adrenal-specific SR-BI-/- mice and the control 
group. As shown in Figure 3.6C, BUN increased only transiently at CLP 4 h and 
decreased to the basal level at CLP 18 h in the control mice. In contrast, in the 
adrenal-specific SR-BI-/- mice, although BUN only increased slightly at CLP 4 h, it 
continued to increase by 2.4-fold at CLP 18 h (68.5 ± 9.0 mg/dl vs. 28.8 ± 2.6 
mg/dl, p=0.002, ANOVA), leading to a significantly higher BUN level than that in 
the control mice at CLP 18 h (68.5 ± 9.0 mg/dl vs. 27.9 ± 6.1 mg/dl, p=0.036, t 
test). These data suggest that iGC prevents kidney injury in sepsis. 
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Figure 3.6 Inducible GC prevents kidney injury in CLP.  
CLP (21-gauge needle, half ligation) surgery was conducted on mice 6 weeks after 
adrenal transplantation. Samples were harvested from CLP 0 h, 4 h and 18 h mice for 
assays. (A) Liver injury was indicated by an elevation of plasma alanine 
aminotransferase (ALT). (B) Lung edema was indicated by an increase in lung W/D ratio. 
(C) Kidney injury was evaluated by detecting the levels of blood urea nitrogen (BUN). 
Data represent mean ± SEM. (n=6-8), * p<0.05, ** p<0.01 
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3.2.2.4 Inducible GC regulates the inflammatory response in sepsis. 
GC is known as a potent anti-inflammatory agent.[221] To investigate 
whether the decreased survival rate in adrenal-specific SR-BI-/- mice is due to an 
expansion of inflammatory cytokines, we assessed the plasma cytokine 
concentrations in the adrenal-specific SR-BI-/- mice in CLP. As shown in Figure 
3.7A and 3.7B, the adrenal-specific SR-BI-/- mice had the same levels of basal 
plasma TNF-α and IL-6 to the control mice, indicating that SR-BI deficiency in 
adrenal does not affect inflammatory cytokines under basal conditions. At CLP 4 
h, the control mice exhibited a 6.6-fold increase in TNF-α (p<0.001, ANOVA) and 
a 50-fold increase in IL-6 (11.6 ± 2.6 ng/ml vs. 0.23 ± 0.19 ng/ml, p=0.044, 
ANOVA). The adrenal-specific SR-BI-/- mice also displayed elevations in TNF-α 
and IL-6 at CLP 4 h. However, they exhibited slightly higher TNF-α (300.8 ± 44.9 
pg/ml vs. 240.9 ± 48.5 pg/ml, p=0.382, t test) and over 2-fold higher IL-6 (26.8 ± 
4.3 ng/ml vs. 11.6 ± 2.6 ng/ml, p=0.012, t test) compared to the control mice at 
the same time point. At CLP 18 h, the TNF-α and IL-6 levels in the control mice 
were markedly decreased compared to their levels at CLP 4 h. Interestingly, the 
TNF-α in the adrenal-specific SR-BI-/- mice also decreased significantly at CLP 
18 h compared to its level at CLP 4 h (137.6 ± 37.7 pg/ml vs. 300.7 ± 44.9 pg/ml, 
p=0.028, ANOVA), although at this time point, the TNF-α in the adrenal-specific 
SR-BI-/- mice was 2.5-fold higher than that in the control mice (137.6 ± 46.1 pg/ml 
vs. 54.4 ± 16.9 pg/ml, p=0.15, t test). More importantly, the IL-6 in the adrenal-
specific SR-BI-/- mice remained at a high level at CLP 18 h, which was 5.4-fold 
higher than that in the control mice at CLP 18 h (22.1 ± 6.8 ng/ml vs. 4.1 ± 2.3 
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ng/ml, p=0.03, t test). These data indicate that iGC inhibits the production of pro-
inflammatory cytokines. 
NO is an important pro-inflammatory mediator to defend invasive bacteria 
during sepsis. However, excess NO damages tissues.[35, 36] Next, we 
measured the plasma nitrite and nitrate (NOx) levels in the adrenal-specific SR-
BI-/- mice to determine whether iGC affects NO production in sepsis. As shown in 
Figure 3.7C, though the NOx concentrations were elevated in both groups by 
CLP, the adrenal-specific SR-BI-/- mice displayed a 2.3-fold higher plasma NOx 
level than the control mice at CLP 4 h (11.48 ± 3.28 µM vs. 5.09 ± 1.21µM, 
p=0.08, t test). At CLP 18 h, the adrenal-specific SR-BI-/- mice exhibited a similar 
plasma NOx level to the control mice (14.76 ± 2.79 µM vs. 12.19 ± 4.08 µM, 
p=0.63, t test). These data indicate that iGC may inhibit NOx production in early 
sepsis. 
We also evaluated the effect of iGC on the production of anti-inflammatory 
cytokine IL-10 during sepsis. As shown in Figure 3.7D, in the control mice, the 
plasma IL-10 increased significantly at CLP 4 h (2908.7 ± 785.3 pg/ml vs. 488.4 
± 141.4 pg/ml, p=0.014, ANOVA) and increased further at CLP 18 h (4034.2 ± 
467.2 pg/ml) compared to the basal level. In the adrenal-specific SR-BI-/- mice, 
the plasma IL-10 also increased at CLP 4 h compared to their basal level (2976.0 
± 848.9 pg/ml vs. 792.2 ± 386.3 pg/ml, p=0.082, ANOVA) but was not higher at 
CLP 18 h compared to the level at CLP 4 h (2885.3 ± 585.8 pg/ml). These data 
indicate that iGC is not responsible for the early production of IL-10 and may 
have a small role in the production of IL-10 cytokine in a later stage of sepsis. 
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Figure 3.7 Inducible GC regulates the inflammatory cytokine production in sepsis.  
The adrenal-specific SR-BI-/- mice and the control mice were subjected to CLP for 0 h, 4 
h or 18 h, and the serum concentrations of TNF-α (A), IL-6 (B), IL-10 (C) and NOx (D) 
were quantified. Data represent mean ± SEM. (n=6-8), * p<0.05 
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Next, we analyzed the correlation between the plasma corticosterone 
concentration and cytokine concentrations.  As shown in Table 3.2, the plasma 
corticosterone showed a significant correlation with the plasma IL-6, but not with 
TNF-α, suggesting that iGC particularly exerts a strong inhibitory effect on IL-6.  
Overall, these results demonstrate that iGC regulates the production of 
cytokines and inflammatory mediators and prevents the overwhelming pro-
inflammatory response during CLP.    
Table 3.2 Correlation between the plasma corticosterone concentration and 
cytokine production in CLP 
 
Data from Figure 2.1 and Figure 3.6 were used for the correlation analysis. Data from 
the adrenal-specific SR-BI-/- mice and the control mice were analyzed together. Pearson 
correlation analysis of the plasma corticosterone concentration and cytokine levels was 
done by SPSS. Data show the correlation efficient (r) and p value (two-tailed). Statistical 
correlations are considered significant at p < 0.05. 
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3.2.2.5 Inducible GC in sepsis increases the phagocytic activity of 
phagocytes in sepsis. 
GC has been considered as an immunosuppressive agent.[101] However, 
the immunosuppression in sepsis is associated with an increased mortality in the 
late phase of sepsis.[52] The phagocytic activity of neutrophils has been reported 
impaired in septic patients [63] and is associated with a high mortality sepsis.[64] 
Therefore, we evaluated the phagocytic activity of phagocytes in the adrenal-
specific SR-BI-/- mice in CLP in vivo [222] to see whether or not iGC suppresses 
phagocytosis in sepsis. The adrenal-specific SR-BI-/- mice and the control mice 
were intravenously injected with 1x108 heat-killed fluorescein isothiocyanate 
(FITC)-labeled E. coli at CLP 17 h. An hour later, the mice were killed for flow 
cytometry. The phagocytosis of injected E. coli by monocytes (CD115+ CD11b+ 
Ly6C+) and neutrophils (Gr-1+ CD11b+) in the blood and macrophages (F4/80+), 
neutrophils (Gr1+ CD11b+) and dendritic cells (CD3-CD11c+) in the spleen was 
analyzed.  
As shown in Figure 3.8A, compared to the control mice, the adrenal-
specific SR-BI-/- mice had a 60% lower percentage of the phagocytic monocytes 
(1.53 ± 0.61 % vs. 3.85 ± 0.85 %, p=0.064) and an unchanged percentage of the 
phagocytic neutrophils (43.78 ± 4.86 % vs. 42.36 ± 7.10 %, p=0.873) in the blood. 
The capability of phagocytosis was evaluated by the mean fluorescence intensity 
(MFI) of E. coli in the phagocytes. We found that the adrenal-specific SR-BI-/- 
mice displayed a 39 % lower MFI of E. coli in monocytes (19.3 ± 3.1 ×103 vs. 
31.6 ± 3.3 ×103, p=0.027) and a 55 % lower MFI of E. coli in neutrophils (9.2 ± 
95 
 
2.7 ×103 vs. 20.1 ± 1.5 ×103, p=0.011) than the control mice (Figure 3.8B), 
demonstrating that iGC can increase the phagocytic capability of monocytes and 
neutrophils in the blood from the CLP-adrenal-specific SR-BI-/- mice.  
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Figure 3.8 Inducible GC in sepsis increases the phagocytic activity of monocytes 
and neutrophils in the blood.  
At CLP 17 h, the adrenal-specific SR-BI-/- mice and the control mice were i.v. injected 
with 1x108 heat-killed FITC-E. coli, and the phagocytosis capability of phagocytes in the 
blood was analyzed by flow cytometry. (A) The percentage of phagocytic monocytes and 
neutrophils in the blood. The left panel shows representative gating pictures for the 
E.coli+ monocytes (upper) and E. coli+ neutrophils (lower). The right panel shows the 
average percentage of E. coli+ monocytes (upper) and neutrophils (lower) in the blood. 
(B)The average of mean fluorescence intensity (MFI) of E.coli in monocytes (left) and 
neutrophils (right) in the blood. Data represent mean ± SEM. (n>4), * p<0.05 
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In the spleen, compared to the control mice, the adrenal-specific SR-BI-/- 
mice had a lower percentage of phagocytic cells, as indicated by a 54 % lower 
percentage of the E. coli+ macrophages (7.19 ± 1.21 % vs. 15.57 ± 4.41 %, 
p=0.131), a 40 % lower percentage of E. coli+ neutrophils (15.54 ± 1.15 % vs. 
25.78 ± 4.83 %, p=0.101) and a 25 % lower percentage of E. coli+ dendritic cells 
(3.92 ± 0.82 % vs. 5.28 ± 0.68 %, p=0.254; Figure 3.9A). In addition, the 
phagocytic capability of macrophages and neutrophils in the spleen also slightly 
decreased in the adrenal-specific SR-BI-/- mice. As shown in Figure 3.9B, the 
adrenal-specific SR-BI-/- mice displayed a 25% decrease in the MFI of E.coli in 
the macrophages (11.4 ± 2.8 vs. 15.2 ± 2.1, p=0.280) and a 32 % decrease in 
the MFI of E.coli in the neutrophils (6.6 ± 1.8 vs. 9.7 ± 2.2, p=0.240), compared to 
the control mice. The MFI of E. coli in the dendritic cells in the spleen from the 
adrenal-specific SR-BI-/- mice was similar to that from the control mice (8.6 ± 1.8 
vs. 7.1 ± 0.9, p=0.457). These results, together with the data from the 
phagocytes in the blood, demonstrate that iGC in sepsis increases the 
phagocytic activity. 
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Figure 3.9 Inducible GC in sepsis trends to increase the phagocytic activity of 
macrophages and neutrophils in the spleen.   
At CLP 17 h, the adrenal-specific SR-BI-/- mice and the control mice were i.v. injected 
with 1x108 heat-killed FITC-E. coli, and the phagocytic capability of macrophages, 
neutrophils and dendritic cells in the spleen was analyzed by flow cytometry. (A) The left 
panel shows representative gating pictures for the E.coli+ macrophages (upper), E. coli+ 
neutrophils (middle) and E. coli+ dendritic cells (lower). The right panel shows the 
average percentage of phagocytic macrophages, neutrophils and dendritic cells in the 
spleen. (B)The average of mean fluorescence index (MFI) of E.coli in macrophage (left), 
neutrophils (middle) and dendritic cells (right) in the spleen. Data represent mean ± SEM. 
(n> 4); DCs, dendritic cells 
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3.2.2.6 Inducible GC in sepsis does not lead more apoptosis but induces 
higher activation of the lymphocytes in the spleen. 
It is known that GC can induce the apoptosis of lymphocytes[223], and the 
apoptosis-induced loss of lymphocytes is considered as a potential factor in the 
immunosuppression of sepsis.[67] To investigate if iGC has such actions in 
sepsis, we evaluated the apoptosis and the activation of lymphocytes in the 
spleen at CLP 18 h. As shown in Figure 3.10A and 3.10B, there was no 
difference between the adrenal-specific SR-BI-/- mice and the control mice in the 
number of spleen cells, the percentage of lymphocytes in spleen cells (66.51 ± 
1.81 % vs. 68.16 ± 1.61 %, p=0.507) and the percentage of T cells (CD3+, 29.61 
± 1.54 % vs. 27.32 ± 1.56 %, p=0.315) or B cells (CD19+, 58.90 ± 1.35 % vs. 
61.72 ± 1.48 %, p=0.186) in lymphocytes in the spleen, indicating that the lack of 
iGC does not affect lymphocyte numbers in the spleen. We then analyzed the 
apoptosis of lymphocytes in the spleen by TUNEL staining. As shown in Figure 
3.10C, we did not observe any difference in the percentage of TUNEL+ cells in 
lymphocytes (3.87 ± 0.81% vs. 3.45 ± 0.29 %, p=0.644), T cells (2.31 ± 0.59 % 
vs. 2.08 ± 0.28 %, p=0.740) and B cells (1.42 ± 0.53 % vs. 0.86 ± 0.11 %, 
p=0.334) between the adrenal-specific SR-BI-/- mice and the control mice, 
indicating that iGC is not associated with the apoptosis-induced loss of 
lymphocytes in sepsis. Using CD69 as an activation marker, we analyzed the 
activation of lymphocytes in the spleen from the adrenal-specific SR-BI-/- mice. 
Interestingly, we observed that the adrenal-specific SR-BI-/- mice had a 
significantly lower percentage of activated T cells (CD69+CD3+) in total 
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lymphocytes compared to the control mice (7.21 ± 0.43 % vs. 5.69 ± 0.35 %, 
p=0.017; Figure 3.10D). Also, the adrenal-specific SR-BI-/- mice had a slightly 
lower percentage of activated B cells (CD69+CD19+) in total lymphocytes than 
the control mice (6.24 ± 0.49 % vs. 4.90 ± 0.63 %, p=0.124; Figure 3.10D). 
These data demonstrate that iGC is not necessarily immunosuppressive but may 
enhance the activation of lymphocytes in sepsis.   
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Figure 3.10 Inducible GC does not lead to more apoptosis but induces higher 
activation of the lymphocytes in the spleen. 
The spleens were harvested from the adrenal-specific SR-BI-/- mice and the control mice 
at CLP 18 h for the flow cytometry. Data show (A) the spleen cell number and the 
lymphocyte percentage in the spleen cells; (B) the percentage of T cells (CD3+) and B 
cells (CD19+) in lymphocytes; (C) the percentages of apoptotic (TUNEL+) cells in total 
lymphocytes, T cells, or B cells; and (D) the activation of T cell and B cells marked by 
CD69. Data represent mean ± SEM. (n=7-9), * p<0.05 
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3.2.3 Summary  
In this section, the important role of iGC in protecting against septic death 
is investigated using the adrenal-specific SR-BI-/- mouse as an iGC deficient 
model. The adrenal-specific SR-BI-/- mice had a high mortality of 87 % in CLP-
induced sepsis whereas only 17 % of the control mice died under the same 
treatment, demonstrating that iGC is important in preventing the sepsis-induced 
death. Compared to the control mice, the adrenal-specific SR-BI-/- mice had a 
high BUN level in the plasma at CLP 18 h, demonstrating an essential role of iGC 
to maintain kidney function during sepsis. Cytokine analysis showed that the 
adrenal-specific SR-BI-/- mice displayed significantly higher levels of plasma IL-6 
at CLP 4 h and CLP 18 h compared to the control mice, a marginally higher level 
of the plasma TNF-α at CLP 18 h and a 2.3-fold higher plasma NOx at CLP 4 h, 
indicating that iGC inhibits the pro-inflammatory cytokines and mediator in sepsis. 
In addition, a strong correlation between the plasma corticosterone and IL-6 was 
observed, indicating that iGC exerts strong inhibitory effects on IL-6 in sepsis. In 
vivo phagocytosis analysis showed that the adrenal-specific SR-BI-/- mice 
presented a lower percentage of phagocytic monocytes in the blood and lower 
percentages of phagocytic macrophages, neutrophils and dendritic cells in the 
spleen at CLP 18 h. In addition, the monocytes and neutrophils from the adrenal-
specific SR-BI-/- mice displayed a reduced phagocytic capability compared to the 
cells from the control mice. These data demonstrate that iGC enhances the 
phagocytic activity of these phagocytes in sepsis. The activation of T cells in the 
spleen from the adrenal-specific SR-BI-/- mice at CLP 18 h was significantly lower 
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than that in the control mice, demonstrating that iGC induces a higher activation 
of lymphocytes in sepsis. The data in this section overall reveal that iGC is 
essential for survival in sepsis and exerts actions of (1) inhibiting the pro-
inflammatory cytokine and mediators, (2) preventing the kidney injury, (3) 
increasing the phagocytic activity of monocytes and neutrophils in the blood and 
(4) enhancing the activation of lymphocytes.  (Figure 3.11) 
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Figure 3.11 The role of SR-BI-regulated iGC in sepsis.  
iGC is produced in sepsis by adrenal glands, which is important for the survival in sepsis. 
Due to the lack of iGC, the adrenal-specific SR-BI-/- mice are very susceptible to death in 
sepsis. In contrast, the control mice survive well in the same CLP treatment. Our data 
revealed that during the sepsis, iGC can (1) inhibit the production pro-inflammatory 
cytokines and mediators, (2) prevent the kidney injury, (3) increase the phagocytic 
activity of monocytes and neutrophils and (4) enhance lymphocyte activation in the 
spleen.  
 
Copyright © Junting Ai 2014 
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Chapter 4 GC supplementation and survival in sepsis 
Section 1 GC supplementation and survival in the CLP-induced septic 
death. 
4.1.1 Introduction 
GC has been given to septic patients for more than five decades, yet GC 
treatment in septic patients got controversial results on survival. Annane. et al 
have shown that low-dose GC supplementation can significantly increase the 
survival rate of septic shock patients who have adrenal insufficiency but cannot 
improve the survival rate of those who do not have adrenal insufficiency.[183] 
However, the Survival Sepsis Campaign used GC in “septic shock patients who 
require vasopressor treatment despite adequate fluid resuscitation” and showed 
no difference in the survival rate between the GC group and the placebo 
group.[190] Using the criteria from the Survival Sepsis Campaign, several other 
trials also revealed no benefit of GC use in sepsis.[191, 192] The reason why GC 
failed to improve sepsis survival in these trials remains unknown.    
We suspected that distinguishing adrenal insufficient patients or not may 
have made a difference in the results of previous trials. We hypothesized that GC 
supplementation improves survival of adrenal insufficient individuals in sepsis but 
not that of individuals without adrenal insufficiency. To test this hypothesis, we 
first investigated whether GC supplementation is beneficial for SR-BI-/- mice, 
which are adrenal insufficient in sepsis. We used two approaches to supplement 
GC to SR-BI-/- mice. The first approach was by transplanting a SR-BI+/+ adrenal 
gland to adrenalectomized SR-BI-/- mice; the second was by injecting GC to the 
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SR-BI-/- mice. We found that GC injections increased the survival rate of SR-BI-/- 
mice in CLP. Then we also tested if GC supplementation benefits individuals 
without adrenal insufficiency by injecting the same GC to SR-BI+/+ mice in CLP. 
We found that GC supplementation that improved survival of SR-BI-/- mice failed 
to increase the survival rate of SR-BI+/+ mice in CLP. Altogether, the results from 
this section support our hypothesis that GC supplementation improves survival of 
adrenal insufficient individuals in sepsis but not that of individuals without adrenal 
insufficiency. 
  
4.1.2 Results 
4.1.2.1 Survival in sepsis is positively associated with the strength of 
corticosterone response. 
To test our hypothesis, we first sought to restore iGC of SR-BI-/- mice by 
transplanting SR-BI+/+ adrenal to these mice. By comparing the corticosterone 
concentration of the SR-BI+/+ → SR-BI-/- mice with that of SR-BI+/+ → SR-BI+/+ 
mice post CLP, we observed a significantly lower production of iGC in the SR-
BI+/+ → SR-BI-/- mice compared to the SR-BI+/+ → SR-BI+/+ mice at CLP 4 h 
(Figure 4.1A). Nevertheless, the plasma corticosterone concentration at CLP 4 h 
showed a significant correlation with the survival time in the SR-BI+/+ → SR-BI-/- 
mice (Figure 4.1B) and the average plasma corticosterone concentration in the 
survivors was significantly higher than that in the non-survivors (Figure 4.1C) in 
these mice. When we divided these mice into responders (C>200 ng/ml) and 
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non-responders (C≤200 ng/ml) by their plasma corticosterone at CLP 4 h, we 
found that the responders had a significantly improved survival compared to the 
non-responders (p=0.049, Figure 4.1D). These data demonstrate that survival in 
sepsis is positively correlated with the strength of corticosterone response. 
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Figure 4.1 The strength of corticosterone response is positively correlated with 
the survival time in CLP-induced sepsis.  
SR-BI-/- mice were transplanted with SR-BI+/+ adrenal gland (SR-BI+/+→SR-BI-/-) and 
subjected to CLP surgery 6 weeks after the transplantation. Plasma was harvested 
though tail bleeding 4 hours after CLP. (A) The plasma corticosterone level at CLP 4 h in 
the SR-BI+/+→SR-BI-/- mice was compared with that in the SR-BI+/+→SR-BI+/+ mice. The 
line shows the mean.  *** p<0.001 (B), (C) and (D) show further analysis of data from the 
SR-BI+/+→SR-BI-/- group. (B) The level of plasma corticosterone concentrations 4 h post 
CLP is positively related with the survival time (r=0.692, p=0.006, Pearson correlation). 
(C) The average plasma corticosterone level from non-survivors was significantly lower 
than that in survivors. Data represent mean ± SEM. * p<0.05 (D) The SR-BI+/+→SR-BI-/- 
mice were divided into a high corticosterone group (C>200ng/ml) and a low 
corticosterone group (C≤200ng/ml) according to the CLP 4 h plasma corticosterone 
concentration. The low corticosterone group had a mortality of 85% while the high 
corticosterone group had a mortality of 42% (p=0.049, log-rank x2 test). * p<0.05      
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4.1.2.2 GC supplementation improves the survival of adrenal insufficient 
mice in CLP-induced sepsis. 
Compared to adrenal transplantation, GC infusion is a more feasible 
strategy to be used in clinical patients; therefore we applied GC injections to 
further study the benefits of GC supplementation in adrenal insufficient mice. In 
our earlier studies, we used corticosterone supplementation through drinking 
water [110] and dexamethasone and fludrocortisones supplementation through 
i.p. injections [224]; however, both approaches failed to improve survival of SR-
BI-/- mice in CLP-induced sepsis. Considering that the dose and kind of 
supplemented GC may affect the results in survival study, in this study, we used 
a corticosteroid cocktail containing 100 µg hydrocortisone, 25 ng fludrocortisone 
acetate and 20 µg methylprednisolone, which was modified from previous 
publication.[225] As shown in Figure 4.2A, administration of the GC cocktail 
increased the survival rate in the SR-BI-/- mice from 40% to 92% (p<0.001). Then, 
because hydrocortisone is recommended in the 2012 surviving sepsis guideline, 
we studied the effects of hydrocortisone supplementation to the survival of the 
SR-BI-/- mice in CLP. Supplementation of 100 µg hydrocortisone alone increased 
the survival rate of SR-BI-/- mice to 70% (p=0.07; Figure 4.2B). Finally, we also 
supplemented the natural GC, corticosterone, to the mice. Supplementation of 
200 µg corticosterone increased the survival rate of SR-BI-/- mice to 80% 
(p=0.067; Figure 4.2C). These data demonstrate that GC supplementation is 
beneficial for the survival of adrenal insufficient mice in sepsis. 
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Figure 4.2 GC supplementation increases the survival rate of SR-BI-/- mice in CLP.  
CLP (23-gauge needle, half ligation) was conducted on SR-BI-/- mice. For GC 
supplementation, the mice were administrated with (A) a GC cocktail containing 100 µg 
hydrocortisone, 25 ng fludrocortisone acetate and 20 µg 6δ-methylprednisolone (+ 
Cocktail), (B) 100 µg hydrocortisone only (+ Hydro) or (C)200 µg corticosterone (+ Cort). 
The control mice received no GC supplementation. Survival was observed for 7 days. 
Data are expressed as the percentage of mice surviving at the indicated time points and 
analyzed by the log-rank x2 test. *** p<0.001 
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4.1.2.3 GC supplementation is unhelpful for the survival of wild type mice in 
CLP-induced sepsis. 
Based on the above results, it seems that GC supplementation is 
beneficial to adrenal insufficient mice in CLP-induced sepsis. However, this did 
not explain why clinical trials on the use of GC in septic patients got controversial 
results. We hypothesized that GC supplementation may only benefit adrenal 
insufficient individuals in sepsis but not those without adrenal insufficiency. We 
conducted CLP in SR-BI+/+ mice using the same condition as that in SR-BI-/- mice. 
CLP which caused a 60 % mortality in the SR-BI-/- mice (Figure 4.2) only induced 
an 20% mortality in the SR-BI+/+ mice (Figure 4.3A), which was consistent with 
former reports [110]. Nevertheless, GC supplementation failed to increase the 
survival rate in the SR-BI+/+ mice in CLP, indicating that GC supplementation 
does not benefit survival of SR-BI+/+ mice in sepsis (Figure 4.3A). When we 
conducted a stronger CLP to SR-BI+/+ mice and injected 200µg/mouse 
corticosterone to the mice, the SR-BI+/+ mice with GC supplementation showed a 
lower survival rate than the SR-BI+/+ mice without GC supplementation (80 % vs. 
40 %, p=0.013; Figure 4.3B).These data demonstrate that GC supplementation is 
unhelpful for survival of mice without adrenal insufficiency in sepsis. 
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Figure 4.3 GC supplementation is unhelpful for survival of SR-BI+/+ mice in CLP-
induced sepsis. 
(A) SR-BI+/+ mice were treated with CLP (23-gauge needle, half ligation) and were 
supplemented with or without a GC cocktail containing 100 µg hydrocortisone, 25 ng 
fludrocortisone acetate and 20 µg 6δ-methylprednisolone after CLP. Survival was 
observed for 7 days. (B) SR-BI+/+ mice were treated with CLP (22-gauge needle, full 
ligation) and were supplemented with or without 200 µg corticosterone after CLP. 
Survival was observed for 5 days. Data are expressed as the percentage of mice 
surviving at the indicated time points and analyzed by the log-rank x2 test. *, p<0.05
116 
 
4.1.3 Summary 
The study in this section investigated the effects of GC supplementation 
on survival in CLP-induced septic death. We hypothesized that GC 
supplementation is beneficial for the individuals with adrenal insufficiency but not 
for those without adrenal insufficiency in sepsis. First, by transplanting SR-BI+/+ 
adrenal glands to the adrenalectomized SR-BI-/- mice, we observed that plasma 
corticosterone level at CLP 4 h was strongly correlated with the survival time of 
the SR-BI+/+ → SR-BI-/- mice in CLP-induced sepsis. Second, we injected a GC 
cocktail containing 100 µg hydrocortisone, 25 ng fludrocortisone acetate and 20 
µg 6δ-methylprednisolone to the SR-BI-/- mice, which increased the survival rate 
of SR-BI-/- mice from 40 % to 92 %. Supplementation of 100 µg hydrocortisone or 
200 µg corticosterone can also increase the survival of SR-BI-/- mice to 70 % or 
80 %, respectively. These data demonstrate that GC supplementation can 
improve the survival of adrenal insufficient mice. In SR-BI+/+ mice, injections of 
GC cocktail or corticosterone did not increase their survival rates in CLP, 
demonstrating that GC supplementation is unhelpful for the individuals without 
adrenal insufficiency in sepsis.  
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Section 2 GC supplementation and survival in the “two-hit” model of 
secondary infection-induced death in sepsis. 
4.2.1 Introduction 
Whereas some patients rapidly succumb to the overwhelming pro-
inflammatory cytokine-driven inflammation and died at an early time after the 
initiation of sepsis, more than 60 % of deaths in sepsis are estimated to occur 
after the first 3 days of the disorder.[54] Thus an investigation on the effects of 
GC on the survival in the late stage of sepsis is also needed. A “two-hit” model 
has been used to study the late stage of CLP-induced sepsis in mice.[71] The 
rationale of this model is based on the fact that nosocomial infection of septic 
patients contributes to the late death of septic patients.[55] In the “two-hit”  model, 
the CLP is used as the “first hit” and an infection of sublethal-dose Pseudomonas 
aeruginosa or Streptococcus pneumonia is used to induce pneumonia in mice 
after CLP as the “second hit”. P. aeruginosa is a gram-negative bacterium that is 
one of the most common causes of nosocomial pneumonia and therefore has 
been used in our study.[226] In this section, we used P. aeruginosa-induced 
secondary infection in CLP mice to address the importance of iGC in secondary 
infection in sepsis.  
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4.2.2 Results 
4.2.2.1 The “two-hit” model of secondary infection in sepsis was generated 
by infection with sublethal-dose P. aeruginosa after CLP. 
After identifying the benefit of GC supplementation in adrenal insufficient 
individuals in the “first insult” in the sepsis, we used a “two-hit” model to evaluate 
the importance of iGC and the effects of GC supplementation in the secondary 
infection in sepsis. According to previous studies using the “two-hit” model, a 
decrease in survival in secondary pneumonia infection can be observed in mice 
that were infected 3 days or 4 days after CLP when innate immune responses 
are impaired, but not in mice that were infected 7 days after CLP when the innate 
immunity is recovered. [226, 227] In our study, a sublethal dose of 5x107 CFU/ 
mouse was identified as an appropriate dose of P. aeruginosa for the secondary 
infection in SR-BI+/+ mice. At this dosage, the non-CLP SR-BI+/+ mice all survived 
the secondary infection, whereas the CLP-3 d SR-BI+/+ mice only had a survival 
rate of 25 % (p<0.001; Figure 4.4A). The CLP-7 d SR-BI+/+ mice had a high 
survival rate which is not significantly different from the survival in non-CLP group 
(Figure 4.4B). This result is consistent with earlier studies on the “two-hit” model 
in sepsis [226, 227]; therefore we used 5x107 CFU/ mouse P. aeruginosa for 
secondary infection in the following experiments.  
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Figure 4.4 A “two-hit” model was generated by a secondary infection of P. 
aeruginosa after CLP. 
A “two-hit” model was generated by a secondary infection of P. aeruginosa in CLP (23-
gauge, half ligation) SR-BI+/+ mice. Mice were challenged with an intranasal 
administration with 5x107 CFU P. aeruginosa without CLP, 3 days after CLP or 7 days 
after CLP. Survival was observed for 10 days after the infection. Data are expressed as 
the percentage of mice surviving at the indicated time points and analyzed by the log-
rank x2 test. *** p<0.001 
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4.2.2.2 CLP-7 d SR-BI-deficient mice have impaired GC production in 
secondary infection in sepsis. 
Next, we investigated the iGC production in the secondary infection model. 
As shown in Figure 4.6B, compared to the non-CLP SR-BI+/+ mice, the CLP-7 d 
SR-BI+/+ mice displayed a lower plasma corticosterone concentration at 4 hours 
post infection (265.3 ± 53.8 µg/ml vs. 160.6 ± 27.3 µg/ml), indicating that less 
iGC is needed for survival in secondary infection than CLP. However, the CLP-7 
d SR-BI-/- mice still showed a significantly lower plasma corticosterone level at 4 
hours post infection compared to the CLP-7 d SR-BI+/+ mice (160.6 ± 27.3 µg/ml 
vs. 23.0 ± 9.0 µg/ml, p<0.001, t test), indicating that CLP-7 d SR-BI-/- mice have 
iGC insufficiency in secondary infection.  
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Figure 4.5 CLP-7 d SR-BI-deficient mice have adrenal insufficiency in secondary 
infection.  
For non-CLP SR-BI+/+ mice, the mice were directly treated with intranasal infection of 
5x107 CFU/mouse P. aeruginosa. For CLP-7 d SR-BI+/+ and SR-BI-/- mice, the mice were 
first subjected to CLP (23-gauge, half ligation). Seven days after CLP, the survived mice 
were infected with P. aeruginosa 5x107 CFU/mouse intranasally. To maintain a high 
survival rate of the SR-BI-/- mice in CLP, the SR-BI-/- mice were injected the GC cocktail 
after CLP. The plasma were harvested through tail bleeding 4 hours after the bacterial 
infection and used for corticosterone assay. Data present mean ± SEM. n=6 for non-CLP 
SR-BI+/+ mice, n=12 for CLP-7 d SR-BI+/+ mice and CLP-7 d SR-BI-/- mice, *** p<0.001  
122 
 
4.2.2.3 CLP-7 d SR-BI-deficient mice are susceptible to the secondary 
infection-induced death in sepsis.  
Since SR-BI-/- mice presented a deficiency of iGC in secondary infection, 
we then used this mice to investigate whether the lack of iGC is associated with 
an increased susceptibility to secondary infection-induced death in sepsis. As 
shown in Figure 4.6A, CLP-7 d SR-BI-/- mice displayed a mortality of ~85 % in 
secondary infection, while CLP-7d SR-BI+/+ mice displayed a mortality of only 
8 % (p<0.001). This result indicates that iGC insufficiency is associated with an 
increased mortality in secondary infection during sepsis.  
 
Figure 4.6 CLP-7 d SR-BI-deficient mice are susceptible to secondary infection-
induced death in sepsis.  
SR-BI+/+ and SR-BI-/- mice were subjected to CLP (23-gauge, half ligation). SR-BI-/- mice 
were injected the GC cocktail after CLP. Seven days after CLP, the survived mice were 
infected with P. aeruginosa 5x107 CFU/mouse intranasally. Survival was observed for 10 
days after the infection. Data are expressed as the percentage of mice surviving at the 
indicated time points and analyzed by the log-rank x2 test. *** p<0.001  
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4.2.2.4 GC injection trends to increase the survival time of SR-BI-deficient 
mice in the second infection after CLP.  
We then tried to rescue SR-BI-/- mice in the secondary infection by GC 
supplementation. Since a lower plasma corticosterone concentration had been 
observed in the CLP-7 d SR-BI+/+ mice than the non-CLP SR-BI+/+ mice, we used 
a half dose of GC cocktail (50µg hydrocortisone, 12.5 ng fludrocortisone acetate 
and 10 µg 6δ-methylprednisolone) for the CLP-7 d SR-BI-/- mice in secondary 
infection. The SR-BI-/- mice were subjected to CLP and received the GC cocktail 
(100 µg hydrocortisone, 25 ng fludrocortisone acetate and 20 µg 6δ-
methylprednisolone) after CLP to maintain a high survival rate. Seven days after 
CLP, the survived SR-BI-/- mice were intranasally administered P. aeruginosa 
with or without the injection of a half-dose GC cocktail after the infection (Figure 
4.7A). As shown in Figure 4.7B, one day after the infection, a 28 % fatality in the 
SR-BI-/- mice with the 2nd GC injection was induced, as controlled by a 23 % 
fatality in those who did not receive the 2nd GC injection. At two days post the 
infection, the fatality of the no 2nd GC injection group increased to 69% while the 
fatality of 2nd GC injection group only elevated to 36%. During the observation 
period, only 8 % mice without the 2nd GC injection finally survived the secondary 
infection challenge, whereas the survival rate increased to 23 % by a 2nd GC 
injection (p=0.282).  
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Figure 4.7 GC injection increases the survival time of SR-BI-deficient mice in 
second infection after CLP.  
(A) The strategy of GC supplementation in secondary infection model. SR-BI-/- mice were 
subjected to CLP (23-gauge, half ligation) and injected with the GC cocktail after CLP 
surgery. Seven days after CLP, mice were intranasally administered 5x107 CFU P. 
aeruginosa with or without the injection of a half-dose GC cocktail after the infection. (B) 
Survival was observed for 10 days after the infection. Data are expressed as the 
percentage of mice surviving at the indicated time and analyzed by the log-rank x2 test. 
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4.2.3 Summary 
In this section, the effect of GC supplementation on survival in secondary 
infection in sepsis was investigated in a “two-hit” model induced by P. aeruginosa 
infection after CLP. First, we figured out the proper dosage of P. aeruginosa for 
the CLP condition and mouse strain in our study. With the infection of 5x107 P. 
aeruginosa, the CLP-3 d SR-BI+/+ mice displayed a survival rate of 25 % and the 
CLP-7 d SR-BI+/+ mice displayed a high survival rate that is non-significantly 
different from the survival in non-CLP group. This result is consistent with 
previous studies on the “two-hit” model, thus we used 5x107 P. aeruginosa to 
induce the secondary infection the following experiments. Next, we showed that 
at 4 hours post infection, the plasma corticosterone concentration in the CLP-7 d 
SR-BI-/- mice was significantly lower than that in the CLP-7 d SR-BI+/+ mice, 
indicating the presence of adrenal insufficiency in the CLP-7 d SR-BI-/- mice. In 
addition, the CLP-7 d SR-BI-/- mice presented a significantly lower survival rate 
than the CLP-7 d SR-BI+/+ mice (15 % vs. 92 %), indicating that the lack of iGC is 
associated with impairs survival in secondary infection in sepsis. Finally, we used 
the CLP-7 d SR-BI-/- mice to study whether or not GC supplementation can 
benefit the mice with adrenal insufficiency in the secondary infection.  
Administration of a half-dose GC cocktail to the SR-BI-/- mice after the secondary 
infection increased the survival rate from 8 % to 23 %, indicating that GC 
supplementation trends to improve the survival of adrenal insufficient mice in the 
secondary infection in sepsis.      
 
Copyright © Junting Ai 2014 
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Chapter 5 Discussion and future directions 
The present dissertation demonstrates the important role of iGC in 
protecting against septic death and the beneficial effects of GC supplementation 
on survival in sepsis. First, by analyzing the difference between the adrenal-
specific SR-BI-deficient mice and the control mice in CLP, we elucidate that iGC 
protects against septic death. The iGC in sepsis has several the functions, which 
includes: (1) preventing the kidney injury, (2) inhibiting the production of pro-
inflammatory cytokines and inflammatory mediators, (3) increasing the 
phagocytosis and (4) enhancing the activation of lymphocytes in sepsis. Then, by 
administrating GC to SR-BI+/+ mice and SR-BI-/- mice, we demonstrate that GC 
supplementation improves survival of mice with adrenal insufficiency during 
sepsis but is unhelpful for survival of mice without adrenal insufficiency. In 
addition, by investigating adrenal insufficiency in the “two-hit” model, we reveal 
that the adrenal insufficiency is associated with a reduced survival rate in 
secondary infection and GC supplementation has a trend to increase the survival 
rate of SR-BI-/- mice in secondary infection in sepsis.  
5.1 Adrenal-specific SR-BI-deficient mice as a model of iGC deficiency 
To investigate the role of iGC in sepsis, we generated adrenal-specific 
SR-BI-/- mice by transplanting SR-BI-/- adrenal to adrenalectomized SR-BI+/+ mice. 
Some phenotypes of the adrenal-specific SR-BI-/- mice have been previously 
studied. Hoekstra et al. measured the fasting plasma corticosterone level in the 
adrenal-specific SR-BI-/- mice and showed that these mice have GC 
insufficiency.[198] Consistent with this study, using CLP, a surgery inducing 
127 
 
septic stress, we observed an impaired production of inducible corticosterone in 
adrenal-specific SR-BI-deficient mice.  
Hoekstra et al. also revealed a decrease in the plasma very-low-density 
and low-density lipoprotein levels in atherogenic diet-fed adrenal-specific SR-BI-
deficient mice, suggesting that adrenal SR-BI may play a role in modulating the 
lipoprotein profile.[198] However, we found that the adrenal-specific SR-BI-/- mice 
under normal diet show no difference in the plasma lipoprotein profile compared 
to the control mice, indicating that adrenal SR-BI deficiency does not affect 
lipoproteins under normal conditions. Actually, unlike normal diet, the atherogenic 
diet itself can stimulate inflammation in the liver [228] and significantly increase 
the plasma corticosterone in mice[229]. Therefore, the changes of the lipoprotein 
profile in the atherogenic diet-fed adrenal-specific SR-BI-deficient mice could be 
a result of iGC insufficiency in the diet-induced inflammation. In addition, in their 
report, the authors concluded that general immune status is not affected in mice 
lacking adrenal SR-BI. In our study, we showed that although the basal immune 
status of the adrenal-specific SR-BI-/- mice is generally normal, these mice are 
very susceptible to septic death due to the lack of iGC.  
It has been reported that adrenalectomized mice have a significant 
increase in the number of mononuclear cells in the blood [219]. Our data show 
that the adrenal-specific SR-BI-/- mice display normal counts of the circulating 
lymphocytes, neutrophils, macrophages and monocytes. Therefore, this result 
clearly demonstrates that the adrenal-specific SR-BI-/- mice are different from the 
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adrenalectomized mice and implies the importance of basal GC in maintaining 
the homeostasis of immunity.  
One limitation of the adrenal transplantation model is the cutoff of the 
communication between the preganglionic sympathetic neuron and the 
chromaffin cell in the adrenal medulla, which are responsible for the secretion of 
catecholamine vasopressors.[230] The lack of hemodynamic effects of 
catecholamine may make the mice more susceptible to sepsis. However, the 
control group and the experimental group were subjected to the same treatment 
(adrenal transplantation); therefore, the neuronal communication is similarly 
disrupted in adrenal-specific SR-BI-/- mice and the control mice, and hence 
should not contribute to the differences between the adrenal-specific SR-BI-/- 
mice and the control group in our endpoints. 
It is worth noting that the response to sepsis in the adrenal specific SR-BI-
deficient mice is different from that in the whole-body SR-BI-deficient (SR-BI-/-) 
mice. Earlier work by our group showed that SR-BI-/- mice display a delayed 
inflammatory response after CLP, as indicated by a delayed generation of pro-
inflammatory cytokines and NOx, partly due to the role of SR-BI in LPS 
recruitment from inflammation site to circulation.[110] In the current study, the 
adrenal-specific SR-BI-deficient mice had a quick inflammatory response upon 
CLP, which implies that the delayed inflammatory response in SR-BI-/- mice is not 
attributed to the lack of iGC. This feature of the adrenal-specific SR-BI-deficient 
mouse also makes it a better model to study adrenal insufficiency in sepsis than 
the whole-body SR-BI-deficient mouse. 
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5.2 GC and acute kidney injury in sepsis 
Sepsis causes multi-organ dysfunction, and kidney is one of the organs 
frequently afflicted.[231] Acute kidney injury (AKI) occurs in about 19 % of 
patients with moderate sepsis, 23 % with severe sepsis and 50 % with septic 
shock when blood cultures are positive.[231] Patients with both sepsis and AKI 
have an mortality rate of 70 %, as compared with a 45 % mortality rate among 
patients with acute renal failure alone.[232] In clinic, AKI is diagnosed by a 
sudden decrease in GFR, the primary measure of kidney function, which is 
currently detected clinically as a rise in serum creatinine and BUN.  
In animal studies, the CLP model does not develop reproducible AKI. AKI 
has been detected by elevation of BUN or creatinine in some [233-236] but not 
other studies [237]. In this study, we used BUN as the marker of AKI and showed 
that the adrenal-specific SR-BI-/- mice, which have iGC deficiency, display an 
abnormally high BUN level at CLP 18 h, whereas the control mice with normal 
iGC production do not develop AKI in sepsis. Our data indicate that iGC protects 
the kidney function in sepsis and the occurrence of AKI may be associated with 
iGC deficiency in sepsis.  
The detailed mechanism of sepsis-associated AKI is unknown. Several 
pathophysiological mechanisms have been proposed: vasodilation-induced 
glomerular hypoperfusion, dysregulated circulation within the peritubular capillary 
network, inflammatory reactions by systemic cytokine storm or local cytokine 
production, tubular dysfunction induced by oxidative stress and disseminated 
intravascular coagulation associated glomerular microthrombi.[238] GC has been 
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known to enhance the suppressor effects of catecholamines that improve the 
perfusion of the kidney and may also alleviate the pathological changes in renal 
tubules in sepsis by reducing mitochondrial damage and apoptosis [239] and 
prevent hypoxic injuries by suppressing iNOS activity after endotoxemia [240]. 
(Figure 4.2) These links between iGC and renal functions may lead future studies 
to understand how iGC protects from kidney injury in sepsis. 
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Figure 5.1 Acute kidney injury (AKI) in sepsis  
Acute renal injury occurs in sepsis due to multiple factors. Sepsis induces the cytokine 
storm and an overwhelming production of reactive oxygen species. Cytokine storm is 
responsible for the endothelial damage, disseminated intravascular coagulation (DIC) 
and excess production of nitric oxide. Endothelial damage and DIC contribute to the 
formation of glomerular microthrombi. Nitric oxide leads to systemic vasodilation and 
simultaneously renal vasoconstriction, which together results in the glomerular 
hypoperfusion and renal ischemia. Reactive oxygen species can directly or indirectly 
damage the tubules. The glomerular microthrombi, renal ischemia and the tubular 
damage overall lead to the acute renal injury in sepsis.[238] GC can enhance the effect 
of catecholamine and therefore increase the perfusion of kidneys. GC may also inhibit 
cytokines and nitric oxide [239] and prevent mitochondria damage-induced apoptosis of 
tubules [240]. 
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5.3 GC and cytokine production in sepsis. 
The suppressive influences of GC on the synthesis of inflammatory 
cytokines and mediators are well documented.[101] Earlier studies showed that 
adrenalectomy leads to an exaggerated production of TNF-α in LPS or bacteria-
induced sepsis [241, 242] and chronic replacement with a 5 mg corticosterone 
pellet inhibits TNF-α and IL-6 in adrenalectomized mice upon the stimulation with 
poly I:C, a ligand of TLR3 [243]. The mechanism by which GC inhibits 
inflammatory cytokine production involves multiple pathways. First, GC inhibits 
the activity of crucial transcriptional regulator of pro-inflammatory genes such as 
NF-κB. Second, GC inhibits inflammatory gene expression at a post-
transcriptional level via destabilization of mRNA or inhibition of translation. Third, 
the GC-induced expression of dual specificity phosphatase 1 (DUSP1) and 
glucocorticoid inducible leucine zipper (GILZ) can interfere with signaling 
pathways that are activated by pro-inflammatory stimuli and hence block pro-
inflammatory gene expression.[244] 
Intriguingly, our results of cytokines in the adrenal-specific SR-BI-/- mouse 
model is different from previous studies using adrenalectomized mice or GC 
supplementation approaches. We provide in vivo evidence that iGC specifically 
regulates the production of IL-6 in sepsis. We show that there is no difference 
between the adrenal-specific SR-BI-/- mice and the control mice in the plasma 
TNF-α level at CLP 4 h, although these mice have a significant difference in the 
plasma corticosterone concentrations at that time. In contrast to TNF-α, IL-6 is 
suppressed in the control mice but not in the adrenal-specific SR-BI-/- mice in 
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CLP. IL-6 has a wider variety of cellular source than TNF-α which is mainly 
produced from macrophages. Many cells including fibroblasts, cells of the 
monocyte-macrophage lineage, endothelial cells and adipocytes can secrete IL-6 
in inflammation.[245-247] Therefore, iGC may also exert the inhibitory effect on 
IL-6 production from other cell types, given the ubiquitous expression of GR. 
Actually, a normal down-regulation of TNF-α has been reported in mice with a 
dimerization-deficient glucocorticoid receptor (GRdim) in LPS-induced septic 
shock, and the authors concluded that a classical transrepression of TNF-α by 
GC is fully functional in the GRdim mice.[248] Based on our data, the normal 
regulation of TNF-α in the GRdim mice could be explained by the cellular 
specificity of iGC action. 
In addition to the different cellular sources, IL-6 presents different 
properties from TNF-α. TNF-α is characterized as a pro-inflammatory 
cytokine.[249] Nevertheless, IL-6 is a pleotropic cytokine that plays disparate 
roles in inflammatory conditions depending on the infection model.[250]  For 
example, it protects the host from death following infection since IL-6 −/− mice 
have higher mortality when infected with Escherichia coli, Klebsiella pneumoniae, 
or Streptococcus pneumonia.[251-254] Treating mice with IL-6-blocking Abs may 
improve survival from CLP by reducing C5a receptor expression [255] or have no 
benefits [256]. A complete lack of IL-6 does not alter mortality in sepsis as 
indicated by no differences in the survival between IL-6 knockout mice and the 
wild types.[257, 258]   
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IL-6 is a candidate marker of sepsis mortality. As early as in 1989, it has 
been found that the plasma IL-6 levels in patients with sepsis are markedly 
increased, particularly in patients who develop a fatal septic shock.[259] Later 
investigations on clinical patients revealed that IL-6 appears to be a good 
candidate marker of severity during bacterial infection.[260, 261] In CLP models, 
a high IL-6 level after CLP also suggests a high mortality.[257] We show that a 
very significant correlation exists between the plasma corticosterone 
concentration and the plasma IL-6 level in CLP-induced sepsis, indicating an 
association between the plasma corticosterone and survival in sepsis. The point 
that plasma GC level is associated with survival in sepsis is also supported by 
our data from the SR-BI+/+ → SR-BI-/- mice.  
IL-10 is known as an important modulator in inflammation. It selectively 
blocks the expression of pro-inflammatory genes encoding cytokines and 
chemokine in myeloid cells activated by PRR ligands and simultaneously 
enhances the expression and production of anti-inflammatory molecules. [262, 
263] It is known that GC can induce the gene expression of IL-10 as one of its 
anti-inflammatory actions[244]. The adrenal-specific SR-BI-/- mice had the same 
IL-10 production as the control mice at CLP 4 h, indicating that the early 
production of IL-10 is not induced by iGC. However, iGC may be involved in 
promoting the IL-10 production in a later stage of sepsis, since we also observed 
higher IL-10 in the control mice than the adrenal-specific SR-BI-/- mice at CLP 18 
h. Because IL-10 can act at the adrenal gland and negatively regulate the 
corticosterone synthesis [264], the iGC-induced increase in IL-10 in a later stage 
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of sepsis could be a homeostatic mechanism to terminate HPA-axis activation 
once inflammation is resolving. 
5.4 GC is not necessarily immunosuppressive.  
GC has been considered as an immune-suppressive agent.[101] However, 
this concept has been challenged by several recent in vitro studies which 
demonstrated that GC has opposing effects on macrophage function dependent 
on the concentration [106, 107] and can significantly increase the phagocytic 
function of cultured human monocytes through regulating genes involved in the 
phagocytosis [108]. Our study revealed that iGC in sepsis significantly enhances 
the phagocytic activity of monocytes and neutrophils in blood and to some extent 
increases the phagocytic macrophages, neutrophils in the spleen in CLP-induced 
sepsis. Thus, we for the first time provide in vivo evidence that iGC is supportive 
to the functions of phagocytes in sepsis.  
Synthetic GC can induce the apoptosis of lymphocytes [104] and inhibit 
the function of T lymphocytes [105]. Experimental and human studies suggest 
that the apoptosis of immune cells, in particular lymphocytes, may contribute to 
the immunosuppressive status in sepsis.[67, 265] We show that compared to the 
control mice, the adrenal-specific SR-BI-/- mice display reduced lymphocyte 
activation in the spleen during CLP, indicating that endogenous iGC is supportive 
for the activation of adaptive immunity. In addition, the number of lymphocytes 
and apoptosis of them were not affected by iGC during sepsis. Overall, our data 
in adrenal-specific SR-BI-/- mice show that iGC in sepsis support the function of 
both innate immunity and adaptive immunity.  
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5.5 GC therapy in sepsis 
Septic patients represent an inhomogeneous group since the individual’s 
immune response can be modulated by a variety of factors, such as the nature of 
the infectious stimuli, the genetic background of the host, the comorbidities, 
exogenous factors, etc. This heterogeneity makes it difficult for physicians and 
scientists to design effective therapies.[74]   
In the last few decades, increasing evidence of relative adrenal 
insufficiency in septic shock evoked a reassessment of hydrocortisone therapy. 
Rather than high-dose GC supplementation used in old studies, low-dose (or 
stress-dose) hydrocortisone infusion has been evaluated for benefits on septic 
patients and is preferred as GC therapy.[169, 266] Actually, in line with our 
finding that iGC modulates the inflammatory responses and prevents kidney 
injury without suppressing the immune response in sepsis, some small clinical 
studies in the early 2000s provided evidence that low-dose hydrocortisone 
therapy may also benefit the septic patients in the same way.  
First, it has been shown that stress-dose hydrocortisone infusion in septic 
patients decreases IL-6 levels but not TNF-α in septic shock patients [267], which 
indicates that low-dose GC may act in the same way as endogenous iGC to 
inhibit pro-inflammatory cytokines in sepsis. Second, clinical studies show that 
low-dose hydrocortisone improves the permeability of the glomerular 
endothelium and normalized free water clearance and renal sodium excretion in 
septic patients [268, 269], which is in consistent with the protective effect of iGC 
on kidney function in sepsis. Third, Keh D et al. showed that the infusion of low-
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dose hydrocortisone does not induce severe monocyte or granulocyte 
dysfunction as indicated by the expression of HLA-DR on monocytes, the 
enhancement of monocyte phagocytosis, and only slightly depressed (2%) 
granulocyte phagocytosis [270], which indicate that low-dose GC is not 
suppressive to the innate immunity in sepsis. Finally, Hotchkiss and colleagues 
observed that low-dose GC treatment had no effect on the rates of lymphocyte 
apoptosis in severe sepsis [66] and Weber et al. showed that low-dose GC 
treatment may not influence the expression of apoptotic genes such as Bim, Bid, 
or Bak in severe sepsis.[271] These studies indicate that low-dose GC can exert 
modulating effects on immune responses that are similar to iGC in sepsis. 
Although the low-dose GC treatment in sepsis showed some benefits on 
organ function [268, 269], the results of mortality in clinical studies remain 
controversial. Current guidelines from the Survival Sepsis Campaign do not 
recommend the diagnosis of adrenal insufficiency before the administration of 
GC in septic patients.[190] Our study provides evidence that GC 
supplementation should be given to the septic patients with adrenal insufficiency. 
Importantly, our data also indicate that for septic individuals without adrenal 
insufficiency, an additional GC supplementation maybe redundant and is 
completely unhelpful. Therefore, we recommend the diagnosis of adrenal 
insufficiency before GC supplementation in septic patients. This finding may also 
explain why the Surviving Sepsis Campaign showed no benefit of GC on survival 
of septic shock patients. In addition, the GC dose currently recommended for 
septic patients may be too high. Considering a factor of 1/12.3 that should be 
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applied when converting a drug dose from mouse to human according to the 
guidance from FDA, the dose of 100 µg hydrocortisone / mouse (~20g) in our 
study is converted to a human dose of  ~61.5mg/kg, which is lower than the 
200mg/kg hydrocortisone used in clinic as the “low-dose”.[272] 
Older application of high-dose GC to septic patients led to an increased 
occurrence of secondary infection. In contrast, the recent randomized controlled 
HYPOLYTE study revealed that in trauma patients, the use of an intravenous 
stress-dose of hydrocortisone can decrease the risk of hospital-acquired 
pneumonia.[273] Our data in the secondary infection model show that iGC is also 
important to prevent secondary infection-induced death in sepsis. We did not use 
CLP-3 d SR-BI-/- mice to investigate this issue, because CLP-3 d mice suffer from 
an unrecovered immune system, which makes it hard to distinguish the effect of 
adrenal insufficiency and that of the weak immunity. We show that after surviving 
the first insult of CLP-induced sepsis with the first injection of GC cocktail, the 
SR-BI-/- mice still suffer from adrenal insufficiency in secondary infection and are 
very susceptible to the secondary infection-induced death. The second injection 
of GC cocktail in a half dose increased the survival time of SR-BI-/- mice in 
secondary infection. The improvement in survival by the second GC injection in 
secondary infection is not as remarkable as that by the first injection in CLP, 
which may due to the lack of SR-BI in other organs and cells, such as the liver 
and macrophages, in the SR-BI-/- mice. Therefore, it will be better to use adrenal-
specific SR-BI-/- mice to demonstrate the benefits of GC supplementation in the 
secondary infection.  
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In conclusion, a model of GC function and supplement stratagem in sepsis 
is proposed (Figure 5.2). Sepsis induced both pro-inflammatory and anti-
inflammatory responses. iGC modulates the balance between anti-inflammatory 
and anti-inflammatory responses and thus helps to survive sepsis. For individuals 
without adrenal insufficiency, iGC regulates the balance and leads to survival in 
sepsis. Additional GC supplementation to these individuals may be unhelpful. For 
individuals with adrenal insufficiency, the lack of iGC leads to the loss of this 
balance, which may result in SIRS when the pro-inflammatory response 
overwhelms and CARS when the anti-inflammatory response dominants. The 
overwhelming cytokine storm in SIRS contributes to the septic death, while the 
immunosuppression in CARS can also lead to death. A proper GC 
supplementation can rescue the mice from systemic inflammation and survive 
CLP-induced sepsis. For the septic individuals that are in a status of CARS, a 
lower amount of GC supplementation may be helpful as well. However, further 
study is needed to investigate the optimal GC supplementation in CARS.     
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Figure 5.2 GC therapy in sepsis.  
Variability in the production of GC upon sepsis influences the outcome of sepsis. Sepsis 
induced both pro-inflammatory and anti-inflammatory responses. iGC plays an important 
role in modulating the balance between pro-inflammatory and anti-inflammatory 
responses, like the balance of fire and water, and thus helps to survive sepsis. For 
individuals without adrenal insufficiency, iGC regulates the balance and leads to survive. 
Additional GC supplementation to these individuals may be unhelpful. For individuals 
with adrenal insufficiency, the lack of iGC leads to the loss of this balance, which may 
result in SIRS when the pro-inflammatory response overwhelms and CARS when the 
anti-inflammatory response dominates. The overwhelming cytokine storm contributes to 
the septic death in SIRS, and the immunosuppression in CARS can also lead to death. 
Optimal GC supplementation can help to control this balance. Our data have 
demonstrated that a proper GC supplementation can rescue the mice from systemic 
inflammation and survive CLP-induced sepsis.  
142 
 
Appendix 
ACK lysis buffer  
0.15 M NH4Cl  
10 mM KHCO3  
0.1 mM EDTA-2Na 
PH=7.4 
Proteinase K solution 
1 M Tris-HCl PH 7.5     0.5 ml 
0.1 M CaCl2      10 ml 
Glycerol     25 ml 
H2O     14.5 ml 
Proteinase K     1 mg 
Lysis buffer for tails for 
genotyping  
50 mM Tris-HCl (PH 8.0)  
RPMI 1640-5 
RPMI 1640 medium      500 ml 
FBS     25 ml 
FACS staining buffer  
DPBS     100 ml 
BSA       1 g 
 
 
 
 
 
 
 
0.45 % NP-40 
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